Гипертрофическая кардиомиопатия. Клинические рекомендации 2025

Российское кардиологическое общество
При участии: Ассоциации сердечно-сосудистых хирургов России, Российского общества медицинских генетиков Одобрено Научно-практическим Советом Минздрава Российской Федерации

1. Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2020;76(25): e159-240. doi:10.1016/j.jacc.2020.08.045.

2. Ommen SR, Ho CY, Asif IM, et al. Writing Committee Members. 2024 AHA/ACC/AMSSM/ HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2024;83(23):2324-405. doi:10.1016/j.jacc.2024.02.014.

3. Elliot P, Zamorano JL, Anastasakis A, et al. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: The task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35(39):2733-79. doi:10.1093/eurheartj/ehu284.

4. Lipshultz SE, Law YM, Asante-Korang A, et al. Cardiomyopathy in Children: Classification and Diagnosis: A Scientific Statement From the American Heart Association. Circulation. 2019;140(1): E9-68. doi:10.1161/CIR.0000000000000682.

5. Bogle C, Colan SD, Miyamoto SD, et al. Treatment Strategies for Cardiomyopathy in Children: A Scientific Statement From the American Heart Association. Circulation. 2023;148(2): Epub ahead of print. doi:10.1161/CIR.0000000000001151.

6. Gurschenkov A, Andreeva S, Zaitsev V, et al. Septal Myectomy in Patients with Hypertrophic Cardiomyopathy and Nonclassical Anderson-Fabry Disease. J Cardiovasc Dev Dis. 2024;11(9):293. doi:10.3390/JCDD11090293.

7. Colan SD, Lipshultz SE, Lowe AM, et al. Epidemiology and cause-specific outcome of hypertrophic cardiomyopathy in children: findings from the Pediatric Cardiomyopathy Registry. Circulation. 2007;115(6):773-81. doi:10.1161/IRCULATIONAHA.106.621185.

8. Monda E, Rubino M, Lioncino M, et al. Hypertrophic Cardiomyopathy in Children: Pathophysiology, Diagnosis, and Treatment of Non-sarcomeric Causes. Front Pediatr. 2021;9:632293. doi:10.3389/FPED.2021.632293.

9. Фетисова С. Г., Мельник О. В., Фомичева Ю. В. и др. Сравнительная информативность применения различных таргетных панелей при генетической диагностике гипертрофической кардиопатии у детей. Трансляционная медицина. 2025;12(1):6-14.

10. Limongelli G, Adorisio R, Baggio C, et al. Diagnosis and Management of Rare Cardiomyopathies in Adult and Paediatric Patients. A Position Paper of the Italian Society of Cardiology (SIC) and Italian Society of Paediatric Cardiology (SICP). Int J Cardiol. 2022;357:55-71. doi:10.1016/J.IJCARD.2022.03.050.

11. Alfares AA, Kelly MA, McDermott G, et al. Results of clinical genetic testing of 2,912 probands with hypertrophic cardiomyopathy: Expanded panels offer limited additional sensitivity. Genet Med. 2015;17(11):880-8. doi:10.1038/gim.2014.205.

12. Ingles J, Sarina T, Yeates L, et al. Clinical predictors of genetic testing outcomes in hypertrophic cardiomyopathy. Genet Med. 2013;15(12):972-7. doi:10.1038/GIM.2013.44.

13. Geisterfer-Lowrance AAT, Kass S, Tanigawa G, et al. A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation. Cell. 1990;62(5):999-1006. doi:10.1016/0092-8674(90)90274-I.

14. Seidman JG, Seidman C. The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms. Cell. 2001;104(4):557-67. doi:10.1016/S00928674(01)00242-2.

15. Seidman CE, Seidman JG. Identifying sarcomere gene mutations in hypertrophic cardiomyopathy: a personal history. Circ Res. 2011;108(6):743-50. doi:10.1161/CIRCRESAHA.110.223834.

16. Liew AC, Vassiliou VS, Cooper R, Raphael CE. Hypertrophic Cardiomyopathy-Past, Present and Future. J Clin Med. 2017;6(12):118. doi:10.3390/JCM6120118.

17. Maron BA, Wang RS, Carnethon MR, et al. What Causes Hypertrophic Cardiomyopathy? Am J Cardiol. 2022;179:74-82. doi:10.1016/j.amjcard.2022.06.017.

18. Maron BJ, Ommen SR, Semsarian C, et al. Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine. J Am Coll Cardiol. 2014;64(1):83-99. doi:10.1016/J.JACC.2014.05.003.

19. Shlyakhto EV, Semernin EN, Gudkova AYa, Kostareva AA. Primary cardiomyopathies, modern concept. Therapeutic Archive. 2005;77(12):77-83. (In Russ.) Шляхто Е. В., Семернин Е. Н., Гудкова А. Я., Костарева А. А. Первичные кардиомиопатии, современное представление. Терапевтический архив. 2005;77(12):77-83.

20. Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: Executive summary: A report of the American College of cardiology foundation/American heart association task force on practice guidelines. Circulation. 2011;124(24):2761-96. doi:10.1161/CIR.0b013e318223e230.

21. Kelly MA, Caleshu C, Morales A, et al. Adaptation and validation of the ACMG/AMP variant classification framework for MYH7-associated inherited cardiomyopathies: Recommendations by ClinGen’s Inherited Cardiomyopathy Expert Panel. Genet Med. 2018;20(3):351-9. doi:10.1038/gim.2017.218.

22. Lopes LR, Murphy C, Syrris P, et al. Use of high-throughput targeted exome-sequencing to screen for copy number variation in hypertrophic cardiomyopathy. Eur J Med Genet. 2015;58(11):611-6. doi:10.1016/j.ejmg.2015.10.001.

23. Maron BJ, Maron MS, Maron BA, Loscalzo J. Moving Beyond the Sarcomere to Explain Heterogeneity in Hypertrophic Cardiomyopathy: JACC Review Topic of the Week. J Am Coll Cardiol. 2019;73(15):1978-86. doi:10.1016/j.jacc.2019.01.061.

24. Zhou N, Qin S, Liu Y, et al. Whole-exome sequencing identifies rare compound heterozygous mutations in the MYBPC3 gene associated with severe familial hypertrophic cardiomyopathy. Eur J Med Genet. 2018;61(8):434-41. doi:10.1016/j.ejmg.2018.03.001.

25. Давыдова В. Г., Гудкова А. Я., Крутиков А. Н. и др. Клинические, морфологические и генетические характеристики пациентов молодого возраста с гипертрофической кардиомиопатией, имеющих показания к имплантации кардиовертерадефибриллятора. Российский кардиологический журнал. 2024;29(11):5994. doi:10.15829/1560-4071-2024-5994.

26. Kostareva A, Gudkova A, Sjöberg G, et al. Deletion in TNNI3 gene is associated with restrictive cardiomyopathy. Int J Cardiol. 2009;131(3):410-2. doi:10.1016/j.ijcard.2007.07.108.

27. Туральчук М. В., Новик Г. А., Гудкова А. Я. Особенности течения кардиомиопатий с рестриктивным фенотипом, обусловленных мутациями генов сердечного тропонина I и десмина, и алгоритмы их диагностики. Педиатрическая фармакология. 2011;8(4):112-6.

28. Ho CY, Day SM, Colan SD, et al. The burden of early phenotypes and the influence of wall thickness in hypertrophic cardiomyopathy mutation carriers: Findings from the HCMNet study. JAMA Cardiol. 2017;2(4):419-28. doi:10.1001/jamacardio.2016.5670.

29. Tsaturyan AK, Zaklyazminskaya EV, Polyak ME, et al. De Novo Asp219Val Mutation in Cardiac Tropomyosin Associated with Hypertrophic Cardiomyopathy. Int J Mol Sci. 2022;24(1):18. doi:10.3390/IJMS24010018.

30. Ansari-Lari MA, Ali SZ. Fine-Needle Aspiration of Abdominal Fat Pad for Amyloid Detection: A Clinically Useful Test? Diagn Cytopathol. 2004;30(3):178-81. doi:10.1002/dc.10370.

31. Canepa M, Sorensen LL, Pozios I, et al. Comparison of clinical presentation, left ventricular morphology, hemodynamics, and exercise tolerance in obese versus nonobese patients with hypertrophic cardiomyopathy. Am J Cardiol. 2013;112(8):1182-9. doi:10.1016/j. amjcard.2013.05.070.

32. Hodatsu A, Konno T, Hayashi K, et al. Compound heterozygosity deteriorates phenotypes of hypertrophic cardiomyopathy with founder MYBPC3 mutation: Evidence from patients and zebrafish models. Am J Physiol — Hear Circ Physiol. 2014;307(11): H1594-604. doi:10.1152/ajpheart.00637.2013.

33. Charron P, Arad M, Arbustini E, et al. Genetic counselling and testing in cardiomyopathies: A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2010;31(22):2715-28. doi:10.1093/eurheartj/ehq271.

34. Finocchiaro G, Magavern E, Sinagra G, et al. Impact of demographic features, lifestyle, and comorbidities on the clinical expression of hypertrophic cardiomyopathy. J Am Heart Assoc. 2017;6(12): e007161. doi:10.1161/JAHA.117.007161.

35. Blagova O, Alieva I, Kogan E, et al. Mixed Hypertrophic and Dilated Phenotype of Cardiomyopathy in a Patient With Homozygous In-Frame Deletion in the MyBPC3 Gene Treated as Myocarditis for a Long Time. Front Pharmacol. 2020;11:579450. doi:10.3389/FPHAR.2020.579450.

36. Pasquale F, Syrris P, Kaski JP, et al. Long-term outcomes in hypertrophic cardiomyopathy caused by mutations in the cardiac troponin T gene. Circ Cardiovasc Genet. 2012;5(1):10-7. doi:10.1161/CIRCGENETICS.111.959973.

37. Maron BJ, Kragel AH, Roberts WC. Sudden death in hypertrophic cardiomyopathy with normal left ventricular mass. Br Heart J. 1990;63(5):308-10. doi:10.1136/HRT.63.5.308.

38. Walsh R, Buchan R, Wilk A, et al. Defining the genetic architecture of hypertrophic cardiomyopathy: re-evaluating the role of non-sarcomeric genes. Eur Heart J. 2017;38(46):3461-8. doi:10.1093/EURHEARTJ/EHW603.

39. Marian AJ, Braunwald E. Hypertrophic cardiomyopathy: Genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Circ Res. 2017;121(7):749-70. doi:10.1161/CIRCRESAHA.117.311059.

40. Ingles J, Goldstein J, Thaxton C, et al. Evaluating the Clinical Validity of Hypertrophic Cardiomyopathy Genes. Circ Genomic Precis Med. 2019;12(2):57-64. doi:10.1161/CIRCGEN.119.002460.

41. Bagnall RD, Ingles J, Dinger ME, et al. Whole Genome Sequencing Improves Outcomes of Genetic Testing in Patients With Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2018;72(4):419-29. doi:10.1016/J.JACC.2018.04.078.

42. Maron BJ. Clinical Course and Management of Hypertrophic Cardiomyopathy. N Engl J Med. 2018;379(7):655-68. doi:10.1056/NEJMRA1710575.

43. Aslam F, Haque A, Foody JA, Shirani J. The frequency and functional impact of overlapping hypertension on hypertrophic cardiomyopathy: a single-center experience. J Clin Hypertens (Greenwich). 2010;12(4):240-5. doi:10.1111/J.1751-7176.2009.00251.X.

44. Timmis A, Gale CP, Flather M, et al. Cardiovascular disease statistics from the European atlas: inequalities between highand middle-income member countries of the ESC. Eur Hear Journal Qual Care Clin Outcomes. 2018;4(1):1-3. doi:10.1093/EHJQCCO/QCX045.

45. Lopes LR, Losi M-A, Sheikh N, et al. Association between common cardiovascular risk factors and clinical phenotype in patients with hypertrophic cardiomyopathy from the European Society of Cardiology (ESC) EurObservational Research Programme (EORP) Cardiomyopathy/Myocarditis registry. Eur Hear Journal Qual Care Clin Outcomes. 2022;9(1):42-53. doi:10.1093/EHJQCCO/QCAC006.

46. De La Rosa A, Shah M, Shiota T, et al. Comparing echocardiographic characteristics in genotype positive-phenotype positive hypertrophic cardiomyopathy and hypertensive left ventricular hypertrophy. Eur Hear Journal Cardiovasc Imaging. 2022;23(3):340-8. doi:10.1093/EHJCI/JEAB217.

47. Gil TCP, Castier MB, Gondar AFP, et al. Strain Analysis of Left Ventricular Function in the Association of Hypertrophic Cardiomyopathy and Systemic Arterial Hypertension. Arq Bras Cardiol. 2019;113(4):677-84. doi:10.5935/ABC.20190176.

48. Harper AR, Goel A, Grace C, et al. Common genetic variants and modifiable risk factors underpin hypertrophic cardiomyopathy susceptibility and expressivity. Nat Genet. 2021;53(2):135-42. doi:10.1038/S41588-020-00764-0.

49. Wang Z, Zheng Y, Ruan H, et al. The impact of hypertension on the prognosis of patients with hypertrophic cardiomyopathy: a single-center retrospective study. PeerJ. 2023;11: e14614. doi:10.7717/PEERJ.14614.

50. Zhang Y, Liu M-H, Zhang M, et al. Different clinical characteristics and outcomes of hypertrophic cardiomyopathy with and without hypertension: seeking the truth. J Geriatr Cardiol. 2023;20(2):109. doi:10.26599/1671-5411.2023.02.007.

51. Gruner C, Ivanov J, Care M, et al. Toronto hypertrophic cardiomyopathy genotype score for prediction of a positive genotype in hypertrophic cardiomyopathy. Circ Cardiovasc Genet. 2013;6(1):19-26. doi:10.1161/CIRCGENETICS.112.963363.

52. Ежова А. В., Зайцев В. В., Ишмухаметов Г. И. и др. Значение традиционных факторов риска сердечно-сосудистых заболеваний в фенотипических проявлениях гипертрофической кардиомиопатии. Артериальная гипертензия. 2023;29(4):371-9. doi:10.18705/1607-419X-2023-29-4-371-379.

53. Luo Q, Chen J, Zhang T, et al. Retrospective analysis of clinical phenotype and prognosis of hypertrophic cardiomyopathy complicated with hypertension. Sci Rep. 2020;10(1). doi:10.1038/S41598-019-57230-Z.

54. Ingles J, Burns C, Bagnall RD, et al. Nonfamilial Hypertrophic Cardiomyopathy: Prevalence, Natural History, and Clinical Implications. Circ Cardiovasc Genet. 2017;10(2): e001620. doi:10.1161/CIRCGENETICS.116.001620.

55. Maron BJ, Wolfson JK, Epstein SE, Roberts WC. Intramural ("small vessel") coronary artery disease in hypertrophic cardiomyopathy. J Am Coll Cardiol. 1986;8(3):545-57. doi:10.1016/S0735-1097(86)80181-4.

56. Rowin EJ, Maron BJ, Maron MS. The Hypertrophic Cardiomyopathy Phenotype Viewed Through the Prism of Multimodality Imaging: Clinical and Etiologic Implications. JACC Cardiovasc Imaging. 2020;13(9):2002-16. doi:10.1016/J.JCMG.2019.09.020.

57. Bonaventura J, Rowin EJ, Maron MS, Maron BJ. Is Hypertrophic Cardiomyopathy Always a Familial and Inherited Disease? J Am Heart Assoc. 2023;12(12): e028974. doi:10.1161/JAHA.122.028974.

58. Burton D, Abdulrazzak H, Knott A, et al. Two mutations in troponin I that cause hypertrophic cardiomyopathy have contrasting effects on cardiac muscle contractility. Biochem J. 2002;362(2):443-51. doi:10.1042/0264-6021:3620443.

59. Бокерия Л. А., Гудкова А. Я., Созин С. Е. и др. Экспрессия генов матриксной металлопротеиназы-1 (ММР-1), тканевого ингибитора матриксных металлопротеиназ-1 (TIMP-1), коллагена I и III типов в миокарде больных идиопатической гипертрофической кардиомиопатией. Бюллетень НЦССХ им. А. Н. Бакулева РАМН. 2005;6(4):35-42.

60. Gudkova AYa. Characteristics of the course of obstructive hypertrophic cardiomyopathy in adults (literature review and own research results). Arterial hypertension. 2008;14(2, Appendix 2):39-49. (In Russ.) Гудкова А. Я. Характеристика течения обструктивной гипертрофической кардиомиопатии у взрослых (обзор литературы и результаты собственных исследований). Артериальная гипертензия. 2008;14(2, Приложение 2):39-49.

61. Gudkova AYa, Rybakova MG, Bokeria LA, Shlyakhto EV. Hypertrophic cardiomyopathy. Clinical and morphological comparisons. Pathology archive. 2012;74(4):8-11. (In Russ.) Гудкова А. Я., Рыбакова М. Г., Бокерия Л. А., Шляхто Е. В. Гипертрофическая кардиомиопатия. Клинико-морфологические сопоставления. Архив патологии. 2012;74(4):8-11.

62. Гудкова А. Я., Шляхто Е. В. Клеточные механизмы гипертрофии миокарда при гипертрофической кардиомиопатии и эссенциальной артериальной гипертензии. Артериальная гипертензия. 2008;14(4):364-80.

63. Philipson DJ, DePasquale EC, Yang EH, Baas AS. Emerging pharmacologic and structural therapies for hypertrophic cardiomyopathy. Heart Fail Rev. 2017;22(6):879-88. doi:10.1007/s10741-017-9648-x.

64. Roberts R, Sigwart U. Current concepts of the pathogenesis and treatment of hypertrophic cardiomyopathy. Circulation. 2005;112(2):293-6. doi:10.1161/01.CIR.0000146788.30724.0A.

65. Зайцев В. В., Гурщенков А. В., Митрофанова Л. Б. и др. Клиническое значение различных методов оценки миокардиального фиброза при гипертрофической кардиомиопатии. Кардиология. 2020;60(3):44-50. doi:10.18087/cardio.2020.3.n561.

66. Arbelo E, Protonotarios A, Gimeno JR, et al. 2023 ESC Guidelines for the management of cardiomyopathies: Developed by the task force on the management of cardiomyopathies of the European Society of Cardiology (ESC). Eur Heart J. 2023;44(37):3503-626. doi:10.1093/EURHEARTJ/EHAD194.

67. Arbustini E, Narula N, Dec GW, et al. The MOGE(S) classification for a phenotypegenotype nomenclature of cardiomyopathy: Endorsed by the world heart federation. J Am Coll Cardiol. 2013;62(22):2046-72. doi:10.1016/j.jacc.2013.08.1644.

68. Bokhari S, Castaño A, Pozniakoff T, et al. 99mTc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging. 2013;6(2):195-201. doi:10.1161/CIRCIMAGING.112.000132.

69. Charron P, Villard E, Sébillon P, et al. Danon’s disease as a cause of hypertrophic cardiomyopathy: A systematic survey. Heart. 2004;90(8):842-6. doi:10.1136/hrt.2003.029504.

70. Frustaci A, Chimenti C, Doheny D, Desnick RJ. Evolution of cardiac pathology in classic Fabry disease: Progressive cardiomyocyte enlargement leads to increased cell death and fibrosis, and correlates with severity of ventricular hypertrophy. Int J Cardiol. 2017;248:257-62. doi:10.1016/j.ijcard.2017.06.079.

71. Tsai SB, Seldin DC, Wu H, et al. Myocardial infarction with "clean coronaries" caused by amyloid light-chain AL amyloidosis: A case report and literature review. Amyloid. 2011;18(3):160-4. doi:10.3109/13506129.2011.571319.

72. Wilkinson JD, Lowe AM, Salbert BA, et al. Outcomes in children with Noonan syndrome and hypertrophic cardiomyopathy: A study from the Pediatric Cardiomyopathy Registry. Am Heart J. 2012;164(3):442-8. doi:10.1016/j.ahj.2012.04.018.

73. Frustaci A, Russo MA, Chimenti C. Diagnostic contribution of left ventricular endomyocardial biopsy in patients with clinical phenotype of hypertrophic cardiomyopathy. Hum Pathol. 2013;44(1):133-41. doi:10.1016/j.humpath.2012.04.023.

74. Cook A, Giunti P. Friedreich’s ataxia: Clinical features, pathogenesis and management. Br Med Bull. 2017;124(1):19-30. doi:10.1093/bmb/ldx034.

75. Dubrey SW, Hawkins PN, Falk RH. Amyloid diseases of the heart: Assessment, diagnosis, and referral. Heart. 2011;97(1):75-84. doi:10.1136/hrt.2009.190405.

76. Planté-Bordeneuve V, Said G. Familial amyloid polyneuropathy. Lancet Neurol. 2011;10(12):1086-97. doi:10.1016/S1474-4422(11)70246-0.

77. Ibrahim M, Rao C, Ashrafian H, et al. Modern Management of Systolic Anterior Motion of the Mitral Valve. Eur J Cardiothorac Surg. 2012;41:60-70.

78. Deng L, Huang X, Yang C, et al. Numerical simulation study on systolic anterior motion of the mitral valve in hypertrophic obstructive cardiomyopathy. Int J Cardiol. 2018;266:167-73. doi:10.1016/j.ijcard.2018.01.062.

79. Manabe S, Kasegawa H, Arai H, Takanashi S. Management of systolic anterior motion of the mitral valve: a mechanism-based approach. Gen Thorac Cardiovasc Surg. 2018;66(7):379-89. doi:10.1007/s11748-018-0915-0.

80. Ro R, Halpern D, Sahn DJ, et al. Vector flow mapping in obstructive hypertrophic cardiomyopathy to assess the relationship of early systolic left ventricular flow and the mitral valve. J Am Coll Cardiol. 2014;64(19):1984-95. doi:10.1016/j.jacc.2014.04.090.

81. Hymel BJ, Townsley MM. Echocardiographic assessment of systolic anterior motion of the mitral valve. Anesth Analg. 2014;118(6):1197-201. doi:10.1213/ANE.0000000000000196.

82. Sherrid MV, Gunsburg DZ, Moldenhauer S, Pearle G. Systolic anterior motion begins at low left ventricular outflow tract velocity in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2000;36(4):1344-54. doi:10.1016/S0735-1097(00)00830-5.

83. Silbiger JJ. Abnormalities of the Mitral Apparatus in Hypertrophic Cardiomyopathy: Echocardiographic, Pathophysiologic, and Surgical Insights. J Am Soc Echocardiogr. 2016;29(7):622-39. doi:10.1016/j.echo.2016.03.003.

84. Shah JS, Esteban MTT, Thaman R, et al. Prevalence of exercise-induced left ventricular outflow tract obstruction in symptomatic patients with non-obstructive hypertrophic cardiomyopathy. Heart. 2008;94(10):1288-94. doi:10.1136/hrt.2007.126003.

85. Geske JB, Sorajja P, Ommen SR, Nishimura RA. Variability of left ventricular outflow tract gradient during cardiac catheterization in patients with hypertrophic cardiomyopathy. JACC Cardiovasc Interv. 2011;4(6):704-9. doi:10.1016/j.jcin.2011.02.014.

86. Efthimiadis GK, Pagourelias ED, Parcharidou D, et al. Clinical characteristics and natural history of hypertrophic cardiomyopathy with midventricular obstruction. Circ J. 2013;77(9):2366-74. doi:10.1253/circj.CJ-12-1561.

87. Minami Y, Kajimoto K, Terajima Y, et al. Clinical implications of midventricular obstruction in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2011;57(23):2346-55. doi:10.1016/j.jacc.2011.02.033.

88. Yan LR, Zhao SH, Wang HY, et al. Clinical characteristics and prognosis of 60 patients with midventricular obstructive hypertrophic cardiomyopathy. J Cardiovasc Med. 2015;16(11):751-60. doi:10.2459/JCM.0000000000000163.

89. Hang D, Schaff HV, Ommen SR, et al. Combined transaortic and transapical approach to septal myectomy in patients with complex hypertrophic cardiomyopathy. J Thorac Cardiovasc Surg. 2018;155(5):2096-102. doi:10.1016/j.jtcvs.2017.10.054.

90. Pacheco Claudio C, Quesada O, Pepine CJ, Noel Bairey Merz C. Why names matter for women: MINOCA/INOCA (myocardial infarction/ischemia and no obstructive coronary artery disease). Clin Cardiol. 2018;41(2):185-93. doi:10.1002/clc.22894.

91. Аверкина Н. В., Габрусенко С. А., Овчинников А. Г. и др. Оценка перфузии миокарда у больных с гипертрофической кардиомиопатией в сопоставлении с клиническими и эхокардиографическими данными. Терапевтический архив. 2003;75(4):20-5.

92. Аверков О. В., Барбараш О. Л., Бойцов С. А. и др. Дифференцированный подход в диагностике, формулировке диагноза, ведении больных и статистическом учете инфаркта миокарда 2 типа (согласованная позиция). Российский кардиологический журнал. 2019;24(6):7-21. doi:10.15829/1560-4071-2019-6-7-21.

93. Каплунова В. Ю., Шакарьянц В. А., Кожевникова М. В. и др. Гипертрофическая кардиомиопатия и ишемическая болезнь сердца. Варианты сочетанной патологии. Кардиология. 2017;57(12):16-24.

94. Костин С. И. Морфологические и морфометрические особенности гипертрофической кардиомиопатии. Архив патологии. 1989;51(1):47-52.

95. Мухарлямов Н. Кардиомиопатии. Москва, 1990.

96. Aletras AH, Tilak GS, Hsu LY, Arai AE. Heterogeneity of intramural function in hypertrophic cardiomyopathy mechanistic insights from MRI late gadolinium enhancement and highresolution displacement encoding with stimulated echoes strain maps. Circ Cardiovasc Imaging. 2011;4(4):425-34. doi:10.1161/CIRCIMAGING.110.958751.

97. Camici PG, Olivotto I, Rimoldi OE. The coronary circulation and blood flow in left ventricular hypertrophy. J Mol Cell Cardiol. 2012;52(4):857-64. doi:10.1016/j.yjmcc.2011.08.028.

98. Einarsen E, Cramariuc D, Lønnebakken MT, et al. Comparison of Frequency of Ischemic Cardiovascular Events in Patients With Aortic Stenosis With Versus Without Asymmetric Septal Hypertrophy (from the SEAS Trial). Am J Cardiol. 2017;119(7):1082-7. doi:10.1016/j.amjcard.2016.11.064.

99. Foà A, Agostini V, Rapezzi C, et al. Histopathological comparison of intramural coronary artery remodeling and myocardial fibrosis in obstructive versus end-stage hypertrophic cardiomyopathy. Int J Cardiol. 2019;291:77-82. doi:10.1016/j.ijcard.2019.03.060.

100. Kwon DH, Smedira NG, Rodriguez ER, et al. Cardiac Magnetic Resonance Detection of Myocardial Scarring in Hypertrophic Cardiomyopathy. Correlation With Histopathology and Prevalence of Ventricular Tachycardia. J Am Coll Cardiol. 2009;54(3):242-9. doi:10.1016/j.jacc.2009.04.026.

101. Maron MS, Olivotto I, Maron BJ, et al. The Case for Myocardial Ischemia in Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2009;54(9):866-75. doi:10.1016/j.jacc.2009.04.072.

102. Mundhenke M, Schwartzkopff B, Strauer BE. Structural analysis of arteriolar and myocardial remodelling in the subendocardial region of patients with hypertensive heart disease and hypertrophic cardiomyopathy. Virchows Arch. 1997;431(4):265-73. doi:10.1007/s004280050098.

103. Nakamura T, Sakamoto K, Yamano T, et al. Increased plasma brain natriuretic peptide level as a guide for silent myocardial ischemia in patients with non-obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2002;39(10):1657-63. doi:10.1016/S07351097(02)01813-2.

104. Raphael CE, Cooper R, Parker KH, et al. Mechanisms of Myocardial Ischemia in Hypertrophic Cardiomyopathy: Insights From Wave Intensity Analysis and Magnetic Resonance. J Am Coll Cardiol. 2016;68(15):1651-60. doi:10.1016/j.jacc.2016.07.751.

105. Sciagrà R, Calabretta R, Cipollini F, et al. Myocardial blood flow and left ventricular functional reserve in hypertrophic cardiomyopathy: a 13NH3 gated PET study. Eur J Nucl Med Mol Imaging. 2017;44(5):866-75. doi:10.1007/s00259-016-3603-2.

106. Shin YJ, Lee JH, Yoo JY, et al. Clinical significance of evaluating coronary atherosclerosis in adult patients with hypertrophic cardiomyopathy who have chest pain. Eur Radiol. 2019;29(9):4593-602. doi:10.1007/s00330-018-5951-8.

107. Liu W, Sun D, Yang J. Diastolic Dysfunction of Hypertrophic Cardiomyopathy GenotypePositive Subjects Without Hypertrophy Is Detected by Tissue Doppler Imaging: A Systematic Review and Meta-analysis: A. J Ultrasound Med. 2017;36(10):2093-103. doi:10.1002/jum.14250.

108. Covella M, Rowin EJ, Hill NS, et al. Mechanism of Progressive Heart Failure and Significance of Pulmonary Hypertension in Obstructive Hypertrophic Cardiomyopathy. Circ Hear Fail. 2017;10(4): e003689. doi:10.1161/CIRCHEARTFAILURE.116.003689.

109. Germans T, Rüssel IK, Götte MJ, et al. How do hypertrophic cardiomyopathy mutations affect myocardial function in carriers with normal wall thickness? Assessment with cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2010;12(1):13. doi:10.1186/1532-429X-12-13.

110. Huang X, Yue Y, Wang Y, et al. Assessment of left ventricular systolic and diastolic abnormalities in patients with hypertrophic cardiomyopathy using real-time threedimensional echocardiography and two-dimensional speckle tracking imaging. Cardiovasc Ultrasound. 2018;16(1):23. doi:10.1186/s12947-018-0142-y.

111. Бокерия Л. А., Борисов К. В., Синев А. Ф. Улучшение диастолической функции левого и правого желудочков сердца после хирургической коррекции гипертрофической обструктивной кардиомиопатии при помощи оригинального способа. Грудная и сердечно-сосудистая хирургия. 1999;4:4-10.

112. Bravo PE, Luo HC, Pozios I, et al. Late gadolinium enhancement confined to the right ventricular insertion points in hypertrophic cardiomyopathy: An intermediate stage phenotype? Eur Heart J Cardiovasc Imaging. 2016;17(3):293-300. doi:10.1093/ehjci/jev154.

113. Fernández A, Vigliano CA, Casabé JH, et al. Comparison of prevalence, clinical course, and pathological findings of left ventricular systolic impairment versus normal systolic function in patients with hypertrophic cardiomyopathy. Am J Cardiol. 2011;108(4):548-55. doi:10.1016/j.amjcard.2011.03.083.

114. Hiemstra YL, Debonnaire P, van Zwet EW, et al. Development of and Progression of Overt Heart Failure in Nonobstructive Hypertrophic Cardiomyopathy. Am J Cardiol. 2018;122(4):656-62. doi:10.1016/j.amjcard.2018.04.038.

115. Horimoto M, Yokota K, Inoue H, et al. Development of obstructive hypertrophic cardiomyopathy from nonobstructive hypertrophic cardiomyopathy. Am J Cardiol. 1998;82(3):403-5. doi:10.1016/S0002-9149(98)00337-3.

116. Melacini P, Basso C, Angelini A, et al. Clinicopathological profiles of progressive heart failure in hypertrophic cardiomyopathy. Eur Heart J. 2010;31(17):2111-23. doi:10.1093/eurheartj/ehq136.

117. Maron MS, Hauser TH, Dubrow E, et al. Right Ventricular Involvement in Hypertrophic Cardiomyopathy. Am J Cardiol. 2007;100(8):1293-8. doi:10.1016/j.amjcard.2007.05.061.

118. Li M, Zhang L, Zhang Z, et al. Isolated Severe Right Ventricular Hypertrophic Cardiomyopathy. Ann Thorac Surg. 2019;107(1): e23-5. doi:10.1016/J.ATHORACSUR.2018.05.061.

119. Falcone DM, Moore D, Lambert EC. Idiopathic hypertrophic cardiomyopathy involving the right ventricle. Am J Cardiol. 1967;19(5):735-40. doi:10.1016/0002-9149(67)90480-8.

120. Shimizu M, Kawai H, Yokota Y, Yokoyama M. Echocardiographic assessment of right ventricular obstruction in hypertrophic cardiomyopathy. Circ J. 2003;67(10):855-60. doi:10.1253/circj.67.855.

121. Бокерия Л. А., Борисов К. В., Синев А. и др. Результаты медикаментозного и хирургического лечения гипертрофической кардиомиопатии с обструкцией выводных отделов левого и правого желудочков сердца. Грудная и сердечно-сосудистая хирургия. 2004;(2):4-9.

122. Pagourelias ED, Efthimiadis GK, Parcharidou DG, et al. Prognostic Value of Right Ventricular Diastolic Function Indices in Hypertrophic Cardiomyopathy. Eur J Echocardiogr. 2011;12(11):809-17. doi:10.1093/EJECHOCARD/JER126.

123. Shah JP, Yang Y, Chen S, et al. Prevalence and Prognostic Significance of Right Ventricular Dysfunction in Patients With Hypertrophic Cardiomyopathy. Am J Cardiol. 2018;122(11):1932-8. doi:10.1016/j.amjcard.2018.08.043.

124. Sheppard MN, Westaby J, Zullo E, et al. Sudden arrhythmic death and cardiomyopathy are important causes of sudden cardiac death in the UK: results from a national coronial autopsy database. Histopathology. 2023;82(7):1056-66. doi:10.1111/HIS.14889.

125. Кактурский Л. Внезапная смерть (клиническая морфология). Москва, 2000.

126. Ревишвили А. Ш., Шляхто Е. В., Попов С. В. и др. Клинические рекомендации по проведению электрофизиологических исследований, катетерной абляции и применению имплантируемых антиаритмических устройств. Москва, 2017. 701 с. ISBN: 978-5-9500922-0-6.

127. Adabag AS, Casey SA, Kuskowski MA, et al. Spectrum and prognostic significance of arrhythmias on ambulatory Holter electrocardiogram in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005;45(5):697-704. doi:10.1016/j.jacc.2004.11.043.

128. Czosek RJ, Jefferies JL, Khoury PR, et al. Arrhythmic Burden and Ambulatory Monitoring of Pediatric Patients with Cardiomyopathy. Pacing Clin Electrophysiol. 2016;39(5):443-51. doi:10.1111/pace.12835.

129. Desai MY, Mentias A. Risk stratification in hypertrophic cardiomyopathy. Aging (Albany NY). 2019;11(6):1617-8. doi:10.18632/aging.101895.

130. Elliott PM, Poloniecki J, Dickie S, et al. Sudden death in hypertrophic cardiomyopathy: Identification of high risk patients. J Am Coll Cardiol. 2000;36(7):2212-8. doi:10.1016/S0735-1097(00)01003-2.

131. Goyal V, Jassal DS, Dhalla NS. Pathophysiology and prevention of sudden cardiac death. Can J Physiol Pharmacol. 2015;94(3):237-44. doi:10.1139/cjpp-2015-0366.

132. Marrakchi S, Kammoun I, Bennour E, et al. Risk stratification in hypertrophic cardiomyopathy. Herz. 2020;45(1):50-64. doi:10.1007/s00059-018-4700-8.

133. Weissler-Snir A, Adler A, Williams L, et al. Prevention of Sudden Death in Hypertrophic Cardiomyopathy: Bridging the Gaps in Knowledge. Eur Hear J. 2017;38(22):1728-37.

134. Weissler-Snir A, Chan RH, Adler A, et al. Usefulness of 14-Day Holter for Detection of Nonsustained Ventricular Tachycardia in Patients With Hypertrophic Cardiomyopathy. Am J Cardiol. 2016;118(8):1258-63. doi:10.1016/j.amjcard.2016.07.043.

135. Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Europace. 2006;8(9):746-837. doi:10.1093/europace/eul108.

136. Goff ZD, Calkins H. Sudden death related cardiomyopathies — Hypertrophic cardiomyopathy. Prog Cardiovasc Dis. 2019;62(3):212-6. doi:10.1016/j.pcad. 2019.04.001.

137. Zeppenfeld K, Tfelt-Hansen J, De Riva M, et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022;43(40):3997-4126. doi:10.1093/EURHEARTJ/EHAC262.

138. Bois JP, Adams JC, Kumar G, et al. Relation between temperature extremes and symptom exacerbation in patients with hypertrophic cardiomyopathy. Am J Cardiol. 2016;117(6):961-5. doi:10.1016/j.amjcard.2015.12.046.

139. Haghjoo M, Faghfurian B, Taherpour M, et al. Predictors of syncope in patients with hypertrophic cardiomyopathy. PACE — Pacing Clin Electrophysiol. 2009;32(5):642-7. doi:10.1111/j.1540-8159.2009.02338.x.

140. Seggewiß H, Koljaja-Batzner A, Seggewiß K, Meesmann M. Syncope in hypertrophic (obstructive) cardiomyopathy. Herzschrittmachertherapie Und Elektrophysiologie. 2018;29(2):178-82. doi:10.1007/s00399-018-0567-x.

141. Williams L, Frenneaux M. Syncope in Hypertrophic Cardiomyopathy: Mechanisms and Consequences for Treatment. Europace. 2007;9(9):817-22.

142. Farhad H, Seidelmann SB, Vigneault D, et al. Left Atrial structure and function in hypertrophic cardiomyopathy sarcomere mutation carriers with and without left ventricular hypertrophy. J Cardiovasc Magn Reson. 2017;19(1):107. doi:10.1186/s12968-0170420-0.

143. Burstein B, Nattel S. Atrial Fibrosis: Mechanisms and Clinical Relevance in Atrial Fibrillation. J Am Coll Cardiol. 2008;51(8):802-9. doi:10.1016/j.jacc.2007.09.064.

144. Philipson DJ, Rader F, Siegel RJ. Risk factors for atrial fibrillation in hypertrophic cardiomyopathy. Eur J Prev Cardiol. 2019: doi:10.1177/2047487319828474.

145. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration With EACTS. Eur Heart J. 2016;37:2893-962.

146. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the Europea. Eur Heart J. 2021;42(5):373-498. doi:10.1093/EURHEARTJ/EHAA612.

147. Maron BJ, Rowin EJ, Udelson JE, Maron MS. Clinical Spectrum and Management of Heart Failure in Hypertrophic Cardiomyopathy. JACC Hear Fail. 2018;6(5):353-63. doi:10.1016/j.jchf.2017.09.011.

148. Seferović PM, Polovina M, Bauersachs J, et al. Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019;21(5):553-76. doi:10.1002/ejhf.1461.

149. Garg L, Gupta M, Sabzwari SRA, et al. Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical impact, and management. Heart Fail Rev. 2019;24(2):189-97. doi:10.1007/s10741-018-9752-6.

150. Arakelyan MG, Bockeria LA, Vasilieva EY, et al. 2020 Clinical guidelines for Atrial fibrillation and atrial flutter. Russian Journal of Cardiology. 2021;26(7):4594. (In Russ.) Аракелян М. Г., Бокерия Л. А., Васильева Е. Ю. и др. Фибрилляция и трепетание предсердий. Клинические рекомендации 2020. Российский кардиологический журнал. 2021;26(7):4594. doi:10.15829/1560-4071-2021-4594.

151. Donnellan E, Wazni OM, Hanna M, et al. Atrial Fibrillation in Transthyretin Cardiac Amyloidosis: Predictors, Prevalence, and Efficacy of Rhythm Control Strategies. JACC Clin Electrophysiol. 2020;6(9):1118-27. doi:10.1016/J.JACEP.2020.04.019.

152. Marstrand P, Han L, Day SM, et al. Hypertrophic Cardiomyopathy With Left Ventricular Systolic Dysfunction: Insights From the SHaRe Registry. Circulation. 2020;141(17):137183. doi:10.1161/CIRCULATIONAHA.119.044366.

153. Russian Society of Cardiology (RSC) 2020 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology. 2020;25(11):4083. (In Russ.) Российское кардиологическое общество (РКО) Хроническая сердечная недостаточность. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(11):4083. doi:10.15829/1560-4071-2020-4083.

154. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-726. doi:10.1093/EURHEARTJ/EHAB368.

155. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022;79(17): e263-421. doi:10.1016/j.jacc.2021.12.012.

156. Pálinkás ED, Re F, Peteiro J, et al. Pulmonary congestion during Exercise stress Echocardiography in Hypertrophic Cardiomyopathy. Int J Cardiovasc Imaging. 2022;38(12):2593-604. doi:10.1007/S10554-022-02620-0.

157. Maron MS, Finley JJ, Bos JM, et al. Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy. Circulation. 2008;118(15):1541-9. doi:10.1161/CIRCULATIONAHA.108.781401.

158. Towe EC, Bos JM, Ommen SR, et al. Genotype-Phenotype Correlations in Apical Variant Hypertrophic Cardiomyopathy. Congenit Heart Dis. 2015;10(3): E139-45. doi:10.1111/CHD.12242.

159. Rowin EJ, Maron BJ, Haas TS, et al. Hypertrophic Cardiomyopathy With Left Ventricular Apical Aneurysm: Implications for Risk Stratification and Management. J Am Coll Cardiol. 2017;69(7):761-73. doi:10.1016/J.JACC.2016.11.063.

160. Yang K, Song YY, Chen XY, et al. Apical hypertrophic cardiomyopathy with left ventricular apical aneurysm: prevalence, cardiac magnetic resonance characteristics, and prognosis. Eur Hear Journal Cardiovasc Imaging. 2020;21(12):1341-50. doi:10.1093/EHJCI/JEAA246.

161. Calabretta R, Kokomani A, Fumagalli C, et al. Evaluation of stress myocardial blood flow patterns in patients with apical hypertrophic cardiomyopathy. J Nucl Cardiol. 2022;29(4):1946-51. doi:10.1007/S12350-022-02911-Y.

162. Cui L, Suo Y, Zhao Y, et al. Mid-Ventricular Obstructive Hypertrophic Cardiomyopathy and Apical Aneurysm Mimicking Acute ST-Elevation Myocardial Infarction. Ann Noninvasive Electrocardiol. 2016;21(1):98-101. doi:10.1111/ANEC.12284.

163. Mörner S, Johansson B, Henein M. Arrhythmogenic left ventricular apical aneurysm in hypertrophic cardiomyopathy. Int J Cardiol. 2011;151(1): e8. doi:10.1016/J.IJCARD.2010. 02.071.

164. Dilaveris P, Aggeli C, Synetos A, et al. Sustained ventricular tachycardia as a first manifestation of hypertrophic cardiomyopathy with mid-ventricular obstruction and apical aneurysm in an elderly female patient. Ann Noninvasive Electrocardiol. 2017;22(3): e12422. doi:10.1111/ANEC.12422.

165. Pérez-Riera AR, Barbosa-Barros R, de Lucca AA, et al. Mid-ventricular Hypertrophic Obstructive Cardiomyopathy with Apical Aneurysm Complicated with Syncope by Sustained Monomorphic Ventricular Tachycardia. Ann Noninvasive Electrocardiol. 2016;21(6):618-21. doi:10.1111/ANEC.12377.

166. Papanastasiou CA, Zegkos T, Karamitsos TD, et al. Prognostic role of left ventricular apical aneurysm in hypertrophic cardiomyopathy: A systematic review and meta-analysis. Int J Cardiol. 2021;332:127-32. doi:10.1016/J.IJCARD.2021.03.056.

167. Chang HC, Kuo L, Sung SH, et al. Left Ventricular Apical Aneurysm in Fabry Disease: Implications for Clinical Significance and Risk Stratification. J Am Heart Assoc. 2023;12(1): e027041. doi:10.1161/JAHA.122.027041.

168. Terai H, Shimizu M, Ino H, et al. Changes in cardiac sympathetic nerve innervation and activity in pathophysiologic transition from typical to end-stage hypertrophic cardiomyopathy. J Nucl Med. 2003;44(10):1612-7.

169. Ciampi Q, Olivotto I, Peteiro J, et al. Prognostic Value of Reduced Heart Rate Reserve during Exercise in Hypertrophic Cardiomyopathy. J Clin Med. 2021;10(7):1347. doi:10.3390/JCM10071347.

170. Maron BA, Kleiner DE, Arons E, et al. Evidence of Advanced Pulmonary Vascular Remodeling in Obstructive Hypertrophic Cardiomyopathy With Pulmonary Hypertension. Chest. 2023;163(3):678-86. doi:10.1016/J.CHEST.2022.09.040.

171. Re F, Halasz G, Moroni F, et al. Exercise-induced pulmonary hypertension in hypertrophic cardiomyopathy: a combined cardiopulmonary exercise test-echocardiographic study. Int J Cardiovasc Imaging. 2022;38(11):2345-52. doi:10.1007/S10554-022-02671-3.

172. Geske JB, Konecny T, Ommen SR, et al. Surgical myectomy improves pulmonary hypertension in obstructive hypertrophic cardiomyopathy. Eur Heart J. 2014;35(30):2032-9. doi:10.1093/EURHEARTJ/EHT537.

173. Maron BJ, Olivotto I, Spirito P, et al. Epidemiology of Hypertrophic CardiomyopathyRelated Death. Circulation. 2000;102(8):858-64. doi:10.1161/01.CIR.102.8.858.

174. Semsarian C, Ingles J, Maron MS, Maron BJ. New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2015;65(12):1249-54. doi:10.1016/j.jacc.2015.01.019.

175. Maurer MS, Hanna M, Grogan M, et al. Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). J Am Coll Cardiol. 2016;68(2):161-72. doi:10.1016/J.JACC.2016.03.596.

176. Rigopoulos AG, Ali M, Abate E, et al. Advances in the diagnosis and treatment of transthyretin amyloidosis with cardiac involvement. Heart Fail Rev. 2019;24(4):521-33. doi:10.1007/S10741-019-09776-3.

177. Amano Y, Kitamura M, Takayama M, et al. MRI classification of asymmetric septal hypertrophic cardiomyopathy and its relation to the presence of risk factors. Int J Cardiovasc Imaging. 2012;28(8):2019-25. doi:10.1007/s10554-012-0034-4.

178. Geske JB, Ommen SR, Gersh BJ. Hypertrophic Cardiomyopathy: Clinical Update. JACC Hear Fail. 2018;6(5):364-75. doi:10.1016/j.jchf.2018.02.010.

179. Neubauer S, Kolm P, Ho CY, et al. Distinct Subgroups in Hypertrophic Cardiomyopathy in the NHLBI HCM Registry. J Am Coll Cardiol. 2019;74(19):2333-45. doi:10.1016/J.JACC.2019.08.1057.

180. Игнатенко Г. А., Тарадин Г. Г., Куглер Т. Е. Особенности гипертрофии левого желудочка и характеристика фенотипических вариантов у больных гипертрофической кардиомиопатией. Архивъ внутренней медицины. 2023;13(4):282-93. doi:10.20514/2226-6704-2023-13-4-282-293.

181. Rapezzi C, Arbustini E, Caforio ALP, et al. Diagnostic work-up in cardiomyopathies: bridging the gap between clinical phenotypes and final diagnosis. A position statement from the ESC Working Group on Myocardial and Pericardial Diseases. Eur Hear J. 2013;34:1448-58.

182. Gudkova A, Kostareva A, Sjoberg G, et al. Diagnostic challenge in desmin cardiomyopathy with transformation of clinical phenotypes. Pediatr Cardiol. 2013;34(2):467-70. doi:10.1007/s00246-012-0312-x.

183. Olivotto I, Cecchi F, Poggesi C, Yacoub MH. Patterns of disease progression in hypertrophic cardiomyopathy an individualized approach to clinical staging. Circ Hear Fail. 2012;5(4):535-46. doi:10.1161/CIRCHEARTFAILURE.112.967026.

184. Argirò A, Zampieri M, Marchi A, et al. Stage-specific therapy for hypertrophic cardiomyopathy. Eur Heart J Suppl. 2023;25(Suppl C): C155-61. doi:10.1093/EURHEARTJSUPP/SUAD042.

185. Rowin EJ, Maron MS, Chan RH, et al. Interaction of Adverse Disease Related Pathways in Hypertrophic Cardiomyopathy. Am J Cardiol. 2017;120(12):2256-64. doi:10.1016/j.amjcard.2017.08.048.

186. Габрусенко С. А., Сафрыгина Ю. В., Овчинников А. Г. и др. Клинико-гемодинамический статус и сердечные натрийуретические пептиды в плазме больных гипертрофической кардиомиопатией. Кардиологический вестник (Бюллетень РКНПК). 2006;1(2):25-31.

187. Дземешкевич С. Л., Фролова Ю. В., Ким С. Ю. и др. Анатомические и морфологические признаки диффузно-генерализованной формы гипертрофической кардиомиопатии. Российский кардиологический журнал. 2015;(5):58-63. doi:10.15829/1560-4071-2015-5-58-63.

188. Стрельцова А. А., Гудкова А. Я., Костарева А. А. Фибрилляция предсердий при гипертрофической кардиомиопатии: современные аспекты эпидемиологии, факторов риска, патогенеза и фармакотерапии. Cons Medicum. 2018;20(5):34-9.

189. Стрельцова А. А., Гудкова А. Я., Полякова А. А. и др. Полиморфный вариант rs1739843 гена белка теплового шока 7 (HSPB7) и его связь с вариантами клинического течения и исходами у пациентов с гипертрофической кардиомиопатией (результаты 10-летнего наблюдения). Российский кардиологический журнал. 2019;(10):7-15. doi:10.15829/1560-4071-2019-10-7-15.

190. Harris KM, Spirito P, Maron MS, et al. Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation. 2006;114(3):216-25. doi:10.1161/CIRCULATIONAHA.105.583500.

191. Bos JM, Ommen SR, Ackerman MJ. Genetics of hypertrophic cardiomyopathy: one, two, or more diseases? Curr Opin Cardiol. 2007;22(3):193-9. doi:10.1097/HCO.0b013e3280e1cc7f.

192. Lancellotti P, Pellikka PA, Budts W, et al. The Clinical Use of Stress Echocardiography in Non-Ischaemic Heart Disease: Recommendations from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. J Am Soc Echocardiogr. 2017;30(2):101-38. doi:10.1016/j.echo.2016.10.016.

193. Parato VM, Antoncecchi V, Sozzi F, et al. Echocardiographic diagnosis of the different phenotypes of hypertrophic cardiomyopathy. Cardiovasc Ultrasound. 2016;14(1):30. doi:10.1186/s12947-016-0072-5.

194. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution. Eur J Heart Fail. 2016;18(8):891-975. doi:10.1002/ejhf.592.

195. Maron BJ, McKenna WJ, Danielson GK, et al. American College of Cardiology/ European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy: A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European S. Eur Heart J. 2003;24(21):1965-91. doi:10.1016/S0195-668X(03)00479-2.

196. Merlo M, Pagura L, Porcari A, et al. Unmasking the prevalence of amyloid cardiomyopathy in the real world: results from Phase 2 of the AC-TIVE study, an Italian nationwide survey. Eur J Heart Fail. 2022;24(8):1377-86. doi:10.1002/EJHF.2504.

197. Cantwell JD. Preparticipation physical evaluation: Getting to the heart of the matter. Med Sci Sports Exerc. 1998;30(10):341-4. doi:10.1097/00005768-199810001-00001.

198. Efthimiadis GK, Parcharidou D, Pagourelias ED, et al. Prevalence and Clinical Outcomes of Incidentally Diagnosed Hypertrophic Cardiomyopathy. Am J Cardiol. 2010;105(10):144550. doi:10.1016/j.amjcard.2009.12.066.

199. Harmon KG, Zigman M, Drezner JA. The effectiveness of screening history, physical exam, and ECG to detect potentially lethal cardiac disorders in athletes: A systematic review/ meta-analysis. J Electrocardiol. 2015;48(3):329-38. doi:10.1016/j.jelectrocard.2015.02.001.

200. Raviele A, Giada F, Bergfeldt L, et al. Management of Patients With Palpitations: A Position Paper From the European Heart Rhythm Association. Europace. 2011;13(7):920-34.

201. Attenhofer Jost CH, Turina J, Mayer K, et al. Echocardiography in the evaluation of systolic murmurs of unknown cause. Am J Med. 2000;108(8):614-20. doi:10.1016/S00029343(00)00361-2.

202. Barrett MJ, Ayub B, Martinez MW. Cardiac auscultation in sports medicine: Strategies to improve clinical care. Curr Sports Med Rep. 2012;11(2):78-84. doi:10.1249/JSR.0b013e318249c0ff.

203. Nagueh SF, Phelan D, Abraham T, et al. Recommendations for Multimodality Cardiovascular Imaging of Patients with Hypertrophic Cardiomyopathy: An Update from the American Society of Echocardiography, in Collaboration with the American Society of Nuclear Cardiology, the Society for Cardiovascula. J Am Soc Echocardiogr. 2022;35(6):533-69. doi:10.1016/J.ECHO.2022.03.012.

204. Barcia G, Rachid M, Magen M, et al. Pitfalls in molecular diagnosis of Friedreich ataxia. Eur J Med Genet. 2018;61(8):455-8. doi:10.1016/j.ejmg.2018.03.004.

205. Monserrat L, Gimeno-Blanes JR, Marín F, et al. Prevalence of Fabry Disease in a Cohort of 508 Unrelated Patients With Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2007;50(25):2399-403. doi:10.1016/j.jacc.2007.06.062.

206. Rapezzi C, Quarta CC, Obici L, et al. Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. Eur Hear J. 2013;34(7):520-8.

207. Sarkozy A, Digilio MC, Dallapiccola B. Leopard syndrome. Orphanet J Rare Dis. 2008;3(1): Article number: 13. doi:10.1186/1750-1172-3-13.

208. Scaglia F, Towbin JA, Craigen WJ, et al. Clinical Spectrum, Morbidity, and Mortality in 113 Pediatric Patients with Mitochondrial Disease. Pediatrics. 2004;114(4):925-31. doi:10.1542/peds.2004-0718.

209. Yang Z, Vatta M. Danon disease as a cause of autophagic vacuolar myopathy. Congenit Heart Dis. 2007;2(6):404-9. doi:10.1111/j.1747-0803.2007.00132.x.

210. Yang Z, McMahon CJ, Smith LR, et al. Danon Disease as an Underrecognized Cause of Hypertrophic Cardiomyopathy in Children. Circulation. 2005;112(11):1612-7. doi:10.1161/CIRCULATIONAHA.105.546481.

211. Pagourelias ED, Efthimiadis GK, Kouidi E, et al. Efficacy of various "classic" echocardiographic and laboratory indices in distinguishing the "gray zone" between athlete’s heart and hypertrophic cardiomyopathy: A pilot study. Echocardiography. 2013;30(2):131-9. doi:10.1111/echo.12014.

212. Grogan M, Scott CG, Kyle RA, et al. Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System. J Am Coll Cardiol. 2016;68(10):1014-20. doi:10.1016/J.JACC.2016.06.033.

213. Vergaro G, Castiglione V, Aimo A, et al. N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T hold diagnostic value in cardiac amyloidosis. Eur J Heart Fail. 2023;25(3):1014-20. doi:10.1002/EJHF.2769.

214. Witteles RM, Bokhari S, Damy T, et al. Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice. JACC Heart Fail. 2019;7(8):709-16. doi:10.1016/J. JCHF.2019.04.010.

215. Damy T, Costes B, Hagège AA, et al. Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness. Eur Heart J. 2016;37(23):1826-34. doi:10.1093/EURHEARTJ/EHV583.

216. Maurizi N, Rella V, Fumagalli C, et al. Prevalence of cardiac amyloidosis among adult patients referred to tertiary centres with an initial diagnosis of hypertrophic cardiomyopathy. Int J Cardiol. 2020;300:191-5. doi:10.1016/J.IJCARD.2019.07.051.

217. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405-24. doi:10.1038/gim.2015.30.

218. Ackerman MJ, Priori SG, Willems S, et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Hear Rhythm. 2011;8(8):1308-39. doi:10.1016/J.HRTHM.2011.05.020.

219. Hershberger RE, Givertz MM, Ho CY, et al. Genetic Evaluation of Cardiomyopathy — A Heart Failure Society of America Practice Guideline. J Card Fail. 2018;24(5):281-302. doi:10.1016/j.cardfail.2018.03.004.

220. Wilde AAM, Semsarian C, Márquez MF, et al. European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the state of genetic testing for cardiac diseases. Europace. 2022;24(8):1307-67. doi:10.1002/joa3.12717.

221. Gabrusenko SA, Seleznev DM, Naumov VG. Genetic aspects of hypertrophic cardiomyopathy (literature review). A practicing doctor. 2000;18(2):2-5. (In Russ.) Габрусенко С. А., Селезнёв Д. М., Наумов В. Г. Генетические аспекты гипертрофической кардиомиопатии (обзор литературы). Практикующий врач. 2000;18(2):2-5.

222. Селезнев Д. М., Габрусенко С. А., Парфенова Е. В. и др. Роль мутаций в гене тяжелой цепи сердечного бета-миозина в российской популяции больных с гипертрофической кардиомиопатией. Кардиология. 2005;45(4):15-20.

223. E, et al. Accuracy of European diagnostic criteria for familial hypertrophic cardiomyopathy in a genotyped population. Int J Cardiol. 2003 90(1):33-8. doi:10.1016/S0167-5273(02)00534-X.

224. Дроздов Д. В., Макаров Л. М., Баркан В. С. и др. Регистрация электрокардиограммы покоя в 12 общепринятых отведениях взрослым и детям 2023. Методические рекомендации. Российский кардиологический журнал. 2023;28(10):5631. doi:10.15829/1560-4071-2023-5631. EDN: JAVUJL.

225. Jalanko M, Heliö T, Mustonen P, et al. Novel electrocardiographic features in carriers of hypertrophic cardiomyopathy causing sarcomeric mutations. J Electrocardiol. 2018;51(6):983-9. doi:10.1016/J.JELECTROCARD.2018.07.009.

226. Lakdawala NK, Thune JJ, Maron BJ, et al. Electrocardiographic features of sarcomere mutation carriers with and without clinically overt hypertrophic cardiomyopathy. Am J Cardiol. 2011;108(11):1606-13. doi:10.1016/J.AMJCARD.2011.07.019.

227. Finocchiaro G, Sheikh N, Biagini E, et al. The electrocardiogram in the diagnosis and management of patients with hypertrophic cardiomyopathy. Hear Rhythm. 2020;17(1):142-51. doi:10.1016/J.HRTHM.2019.07.019.

228. Bernardini A, Crotti L, Olivotto I, Cecchi F. Diagnostic and prognostic electrocardiographic features in patients with hypertrophic cardiomyopathy. Eur Heart J Suppl. 2023;25(Suppl C): C173-8. doi:10.1093/EURHEARTJSUPP/SUAD074.

229. McLeod CJ, Ackerman MJ, Nishimura RA, et al. Outcome of Patients With Hypertrophic Cardiomyopathy and a Normal Electrocardiogram. J Am Coll Cardiol. 2009;54(3):229-33. doi:10.1016/j.jacc.2009.02.071.

230. Arima N, Ochi Y, Takahashi M, et al. Transient decrease in the depth of the negative T wave in apical hypertrophic cardiomyopathy is a sign of left anterior descending artery stenosis: a case series. Eur Hear Journal Case Reports. 2023;7(1): ytad034. doi:10.1093/EHJCR/YTAD034.

231. Delcrè SDL, Di Donna P, Leuzzi S, et al. Relationship of ECG findings to phenotypic expression in patients with hypertrophic cardiomyopathy: a cardiac magnetic resonance study. Int J Cardiol. 2013;167(3):1038-45. doi:10.1016/J.IJCARD.2012.03.074.

232. Biagini E, Pazzi C, Olivotto I, et al. Usefulness of Electrocardiographic Patterns at Presentation to Predict Long-term Risk of Cardiac Death in Patients With Hypertrophic Cardiomyopathy. Am J Cardiol. 2016;118(3):432-9. doi:10.1016/J.AMJCARD.2016.05.023.

233. Bi X, Yang C, Song Y, et al. Quantitative fragmented QRS has a good diagnostic value on myocardial fibrosis in hypertrophic obstructive cardiomyopathy based on clinical-pathological study. BMC Cardiovasc Disord. 2020;20(1):298. doi:10.1186/S12872-020-01590-2.

234. Kang KW, Janardhan AH, Jung KT, et al. Fragmented QRS as a candidate marker for highrisk assessment in hypertrophic cardiomyopathy. Hear Rhythm. 2014;11(8):1433-40. doi:10.1016/J.HRTHM.2014.05.002.

235. Fananapazir L, Tracy CM, Leon MB, et al. Electrophysiologic abnormalities in patients with hypertrophic cardiomyopathy. A consecutive analysis in 155 patients. Circulation. 1989;80(5):1259-68. doi:10.1161/01.CIR.80.5.1259.

236. Kelly BS, Mattu A, Brady WJ. Hypertrophic cardiomyopathy: electrocardiographic manifestations and other important considerations for the emergency physician. Am J Emerg Med. 2007;25(1):72-9. doi:10.1016/j.ajem.2006.04.017.

237. Wilke I, Witzel K, Münch J, et al. High Incidence of De Novo and Subclinical Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy and Cardiac Rhythm Management Device. J Cardiovasc Electrophysiol. 2016;27(7):779-84. doi:10.1111/jce.12982.

238. Хирманов В. Н., Трешкур Т. В., Тюрина Т. В. и др. Электрокардиографические методы в диагностике, выборе метода и тактики лечения гипертрофической кардиомиопатии. Prog Biomed Res. 1997;2(1):7-22.

239. O’Mahony C, Jichi F, Pavlou M, et al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM Risk-SCD). Eur Hear J. 2014;35(30): 2010-20. doi:10.1093/eurheartj/eht439.

240. Wasfy MM, Weiner RB. Differentiating the athlete’s heart from hypertrophic cardiomyopathy. Curr Opin Cardiol. 2015:500-5. doi:10.1097/HCO.0000000000000203.

241. Weigner MJ, Caulfield TA, Danias PG, et al. Risk for clinical thromboembolism associated with conversion to sinus rhythm in patients with atrial fibrillation lasting less than 48 hours. Ann Intern Med. 1997;126(8):615-20. doi:10.7326/0003-4819-126-8-199704150-00005.

242. Guttmann OP, Rahman MS, O’Mahony C, et al. Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: Systematic review. Heart. 2014;100(6):46572. doi:10.1136/heartjnl-2013-304276.

243. Brignole M, Auricchio A, Baron-Esquivias G, et al. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. The Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association. Europace. 2013;15(8):1070-118. doi:10.1093/europace/eut206.

244. Brignole M, Vardas P, Hoffman E, et al. Indications for the use of diagnostic implantable and external ECG loop recorders. Europace. 2009;11(5):671-87. doi:10.1093/europace/eup097.

245. Frangini PA, Cecchin F, Jordao L, et al. How revealing are insertable loop recorders in pediatrics? Pacing Clin Electrophysiol. 2008;31(3):338-43. doi:10.1111/j.15408159.2008.00995.x.

246. Solano A, Menozzi C, Maggi R, et al. Incidence, diagnostic yield and safety of the implantable loop-recorder to detect the mechanism of syncope in patients with and without structural heart disease. Eur Heart J. 2004;25(13):1116-9. doi:10.1016/j.ehj.2004.05.013.

247. Алехин М. Н., Бартош-Зеленая С. Ю., Берестень Н. Ф. Стандартизация проведения трансторакальной эхокардиографии у взрослых: консенсус экспертов Российской ассоциации специалистов ультразвуковой диагностики в медицине (РАСУДМ) и Российской ассоциации специалистов функциональной диагностики (РАСФД). Ультразвуковая и функциональная диагностика. 2021;2:63-79. doi:10.24835/1607-0771-2021-2-63-79. EDN MUCMFC.

248. Мареев Ю. В., Джиоева О. Н., Зоря О. Т. и др. Фокусное ультразвуковое исследование в практике врача-кардиолога. Российский согласительный документ. Кардиология. 2021;61(11):4-23. doi:10.18087/CARDIO.2021.11.N1812.

249. Mitchell C, Rahko PS, Blauwet LA, et al. Guidelines for Performing a Comprehensive Transthoracic Echocardiographic Examination in Adults: Recommendations from the American Society of Echocardiography. J Am Soc Echocardiogr. 2018;32(1):1-64. doi:10.1016/j.echo.2018.06.004.

250. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American society of echocardiography and the European association of cardiovascular imaging. Eur Heart J Cardiovasc Imaging. 2015;16(3):233-71. doi:10.1093/ehjci/jev014.

251. Cerqueira M, Weissman N, Dilsizian V, et al. Standardized Myocardial Segmentation and Nomenclature for Tomographic Imaging of the Heart A Statement for Healthcare Professionals From the Cardiac Imaging Committee. Circulation. 2002;105(4):539-42. doi:10.1161/hc0402.102975.

252. Flachskampf F, Badano L, Daniel W, et al. Recommendations for Transoesophageal Echocardiography: Update 2010. Eur J Echocardiogr. 2010;11(7):557-76. doi:10.1093/EJECHOCARD/JEQ057.

253. Nagueh S, Smiseth O, Appleton C, et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Hear J Cardiovasc Imaging. 2016;17(12):1321-60. doi:10.1093/ehjci/jew082.

254. Senior R, Becher H, Monaghan M, et al. Contrast echocardiography: evi.dence-based recommendations by European Association of Echocardiography. Eur J Echocardiogr. 2009;10(2):194-212.

255. Klues HG, Schiffers A, Maron BJ. Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: Morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients. J Am Coll Cardiol. 1995;26(7):1699-708. doi:10.1016/0735-1097(95)00390-8.

256. Maron BJ, Casey SA, Hauser RG, Aeppli DM. Clinical course of hypertrophic cardiomyopathy with survival to advanced age. J Am Coll Cardiol. 2003;42(5):882-8. doi:10.1016/S0735-1097(03)00855-6.

257. Maron BJ, Rowin EJ, Maron MS, Braunwald E. Nonobstructive Hypertrophic Cardiomyopathy Out of the Shadows: Known from the Beginning but Largely Ignored … Until Now. Am J Med. 2017;130(2):119-23. doi:10.1016/j.amjmed.2016.09.015.

258. Maron MS, Olivotto I, Zenovich AG, et al. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation. 2006;114(21):2232-9. doi:10.1161/CIRCULATIONAHA.106.644682.

259. Elliott P, Gimeno J, Tomé M, McKenna W. Left ventricular outflow tract obstruction and sudden death in hypertrophic cardiomyopathy. Eur Heart J. 2006;27(24):3073-4. doi:10.1093/eurheartj/ehl383.

260. Spirito P, Bellone P, Harris KM, et al. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med. 2000;342(24):1778-85. doi:10.1056/NEJM200006153422403.

261. Belenkie I, MacDonald RPR, Smith ER. Localized septal hypertrophy: Part of the spectrum of hypertrophic cardiomyopathy or an incidental echocardiographic finding? Am Heart J. 1988;115(2):385-90. doi:10.1016/0002-8703(88)90486-3.

262. Gardin J, Palabrica T, Dubria S, et al. Localized basal ventricular septal hypertrophy — prevalence, functional and clinical correlates in a population referred for echocardiography. Am J Noninvas Card. 1998;6(1):5-8.

263. Losi MA, Nistri S, Galderisi M, et al. Echocardiography in patients with hypertrophic cardiomyopathy: Usefulness of old and new techniques in the diagnosis and pathophysiological assessment. Cardiovasc Ultrasound. 2010;8(1): Article number: 7. doi:10.1186/1476-7120-8-7.

264. Alvares RF, Goodwin JF. Non-invasive assessment of diastolic function in hypertrophic cardiomyopathy on and off beta adrenergic blocking drugs. Br Heart J. 1982;48(3):20412. doi:10.1136/hrt.48.3.204.

265. Biagini E, Spirito P, Rocchi G, et al. Prognostic Implications of the Doppler Restrictive Filling Pattern in Hypertrophic Cardiomyopathy. Am J Cardiol. 2009;104(12):1727-31. doi:10.1016/j.amjcard.2009.07.057.

266. Matsumura Y, Elliott PM, Virdee MS, et al. Left ventricular diastolic function assessed using Doppler tissue imaging in patients with hypertrophic cardiomyopathy: Relation to symptoms and exercise capacity. Heart. 2002;87(3):247-51. doi:10.1136/heart.87.3.247.

267. Kubo T, Gimeno JR, Bahl A, et al. Prevalence, Clinical Significance, and Genetic Basis of Hypertrophic Cardiomyopathy With Restrictive Phenotype. J Am Coll Cardiol. 2007;49(25):2419-26. doi:10.1016/j.jacc.2007.02.061.

268. Nagueh SF, Appleton CP, Gillebert TC, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr. 2009;10(2):165-93. doi:10.1093/EJECHOCARD/JEP007.

269. Dimitrow PP, Bober M, Michałowska J, Sorysz D. Left ventricular outflow tract gradient provoked by upright position or exercise in treated patients with hypertrophic cardiomyopathy without obstruction at rest. Echocardiography. 2009;26(5):513-20. doi:10.1111/j.1540-8175.2008.00851.x.

270. Nistri S, Olivotto I, Maron MS, et al. Timing and significance of exercise-induced left ventricular outflow tract pressure gradients in hypertrophic cardiomyopathy. Am J Cardiol. 2010;106(9):1301-6. doi:10.1016/j.amjcard.2010.06.057.

271. Olivotto I, Montereggi A, Mazzuoli F, Cecchi F. Clinical utility and safety of exercise testing in patients with hypertrophic cardiomyopathy. G Ital Cardiol. 1999;29:11-9.

272. Sadoul N, Prasad K, Elliott PM, et al. Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy. Circulation. 1997;96(9):2987-91. doi:10.1161/01.CIR.96.9.2987.

273. Tower-Rader A, Betancor J, Lever HM, Desai MY. A Comprehensive Review of Stress Testing in Hypertrophic Cardiomyopathy: Assessment of Functional Capacity, Identification of Prognostic Indicators, and Detection of Coronary Artery Disease. J Am Soc Echocardiogr. 2017;30(9):829-44. doi:10.1016/j.echo.2017.05.017.

274. Cardim N, Galderisi M, Edvardsen T, et al. Role of multimodality cardiac imaging in the management of patients with hypertrophic cardiomyopathy: An expert consensus of the European Association of Cardiovascular Imaging Endorsed by the Saudi Heart Association. Eur Heart J Cardiovasc Imaging. 2015;16(3):280. doi:10.1093/ehjci/jeu291.

275. Kim MS, Klein AJ, Groves BM, et al. Left Ventricular Outflow Tract Obstruction in the Presence of Asymmetric Septal Hypertrophy and Accessory Mitral Valve Tissue Treated With Alcohol Septal Ablation. Eur J Echocardiogr. 2008;9(5):720-4. doi:10.1093/EJECHOCARD/JEN152.

276. Monakier D, Woo A, Puri T, et al. Usefulness of myocardial contrast echocardiographic quantification of risk area for predicting postprocedural complications in patients undergoing septal ethanol ablation for obstructive hypertrophic cardiomyopathy. Am J Cardiol. 2004;94(12):1515-22. doi:10.1016/j.amjcard.2004.08.030.

277. Wallace EL, Thompson JJ, Faulkner MW, et al. Septal perforator anatomy and variability of perfusion bed by myocardial contrast echocardiography: A study of hypertrophic cardiomyopathy patients undergoing alcohol septal ablation. J Interv Cardiol. 2013;26(6):604-12. doi:10.1111/joic.12068.

278. Spirito P, Autore C, Formisano F, et al. Risk of sudden death and outcome in patients with hypertrophic cardiomyopathy with benign presentation and without risk factors. Am J Cardiol. 2014;113(9):1550-5. doi:10.1016/j.amjcard.2014.01.435.

279. Grigg LE, Wigle ED, Williams WG, et al. Transesophageal Doppler echocardiography in obstructive hypertrophic cardiomyopathy: Clarification of pathophysiology and importance in intraoperative decision making. J Am Coll Cardiol. 1992;20(1):42-52. doi:10.1016/0735-1097(92)90135-A.

280. Oki T, Fukuda N, Iuchi A, et al. Transesophageal echocardiographic evaluation of mitral regurgitation in hypertrophic cardiomyopathy: Contributions of eccentric left ventricular hypertrophy and related abnormalities of the mitral complex. J Am Soc Echocardiogr. 1995;8(4)503-10. doi:10.1016/S0894-7317(05)80338-4.

281. Yu EHC, Omran AS, Wigle ED, et al. Mitral regurgitation in hypertrophic obstructive cardiomyopathy: Relationship to obstruction and relief with myectomy. J Am Coll Cardiol. 2000;36(7):2219-25. doi:10.1016/S0735-1097(00)01019-6.

282. Marwick TH, Stewart WJ, Lever HM, et al. Benefits of intraoperative echocardiography in the surgical management of hypertrophic cardiomyopathy. J Am Coll Cardiol. 1992;20(5):1066-72. doi:10.1016/0735-1097(92)90359-U.

283. Huurman R, Van Der Velde N, Schinkel AFL, et al. Contemporary family screening in hypertrophic cardiomyopathy: the role of cardiovascular magnetic resonance. Eur Hear Journal Cardiovasc Imaging. 2022;23(9):1144-54. doi:10.1093/EHJCI/JEAC099.

284. Bois JP, Geske JB, Foley TA, et al. Comparison of Maximal Wall Thickness in Hypertrophic Cardiomyopathy Differs Between Magnetic Resonance Imaging and Transthoracic Echocardiography. Am J Cardiol. 2017;119(4):643-50. doi:10.1016/J.AMJCARD.2016.11.010.

285. Гурщенков А. В., Моисеева О. М., Зайцев В. В. и др. Анализ анатомии межжелудочковой перегородки при обструктивных формах гипертрофической кардиомиопатии. Кардиология и сердечно-сосудистая хирургия. 2025;18(1):15-22. doi:10.17116/kardio20251801115.

286. Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation. 2005;112(13):2047-60. doi:10.1161/CIRCULATIONAHA.104.489187.

287. Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133(24):2404-12. doi:10.1161/CIRCULATIONAHA.116.021612.

288. Quarta CC, Guidalotti PL, Longhi S, et al. Defining the diagnosis in echocardiographically suspected senile systemic amyloidosis. JACC Cardiovasc Imaging. 2012;5(7):755-8. doi:10.1016/j.jcmg.2012.02.015.

289. Syed IS, Glockner JF, Feng DL, et al. Role of Cardiac Magnetic Resonance Imaging in the Detection of Cardiac Amyloidosis. JACC Cardiovasc Imaging. 2010;3(2):155-64. doi:10.1016/j.jcmg.2009.09.023.

290. Vogelsberg H, Mahrholdt H, Deluigi CC, et al. Cardiovascular Magnetic Resonance in Clinically Suspected Cardiac Amyloidosis. Noninvasive Imaging Compared to Endomyocardial Biopsy. J Am Coll Cardiol. 2008;51(10):1022-30. doi:10.1016/j.jacc.2007.10.049.

291. Dungu JN, Valencia O, Pinney JH, et al. CMR-based differentiation of AL and ATTR cardiac amyloidosis. JACC Cardiovasc Imaging. 2014;7(2):133-42. doi:10.1016/J. JCMG.2013.08.015.

292. Moon JCC, Fisher NG, McKenna WJ, Pennell DJ. Detection of apical hypertrophic cardiomyopathy by cardiovascular magnetic resonance in patients with non-diagnostic echocardiography. Heart. 2004;90(6):645-9. doi:10.1136/hrt.2003.014969.

293. O’Hanlon R, Assomull RG, Prasad SK. Use of cardiovascular magnetic resonance for diagnosis and management in hypertrophic cardiomyopathy. Curr Cardiol Rep. 2007;9(1):51-6. doi:10.1007/s11886-007-0010-0.

294. Webb J, Fovargue L, Tøndel K, et al. The Emerging Role of Cardiac Magnetic Resonance Imaging in the Evaluation of Patients with HFpEF. Curr Heart Fail Rep. 2018;15(1):1-9. doi:10.1007/s11897-018-0372-1.

295. Patel P, Dhillon A, Popovic ZB, et al. Left ventricular outflow tract obstruction in hypertrophic cardiomyopathy patients without severe septal hypertrophy: Implications of mitral valve and papillary muscle abnormalities assessed using cardiac magnetic resonance and echocardiography. Circ Cardiovasc Imaging. 2015;8(7): e003132. doi:10.1161/CIRCIMAGING.115.003132.

296. Olivotto I, Maron MS, Autore C, et al. Assessment and Significance of Left Ventricular Mass by Cardiovascular Magnetic Resonance in Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2008;52(7):559-66. doi:10.1016/j.jacc.2008.04.047.

297. Rudolph A, Abdel-Aty H, Bohl S, et al. Noninvasive Detection of Fibrosis Applying Contrast-Enhanced Cardiac Magnetic Resonance in Different Forms of Left Ventricular Hypertrophy. Relation to Remodeling. J Am Coll Cardiol. 2009;53(3):284-91. doi:10.1016/j.jacc.2008.08.064.

298. Gruner C, Chan RH, Crean A, et al. Significance of left ventricular apical-basal muscle bundle identified by cardiovascular magnetic resonance imaging in patients with hypertrophic cardiomyopathy. Eur Heart J. 2014;35(39):2706-13. doi:10.1093/eurheartj/ehu154.

299. Brouwer WP, Germans T, Head MC, et al. Multiple myocardial crypts on modified longaxis view are a specific finding in pre-hypertrophic HCM mutation carriers. Eur Hear J Cardiovasc Imaging. 2012;13(4):292-7. doi:10.1093/ehjci/jes005.

300. Sado DM, White SK, Piechnik SK, et al. Identification and assessment of anderson-fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping. Circ Cardiovasc Imaging. 2013;6(3):392-8. doi:10.1161/CIRCIMAGING.112.000070.

301. Maron BJ, Pelliccia A, Spirito P. Cardiac disease in young trained athletes: Insights into methods for distinguishing athlete’s heart from structural heart disease, with particular emphasis on hypertrophic cardiomyopathy. Circulation. 1995;91(5):1596-601. doi:10.1161/01.CIR.91.5.1596.

302. Schroeder S, Achenbach S, Bengel F, et al. Cardiac Computed Tomography: Indications, Applications, Limitations, and Training Requirements: Report of a Writing Group Deployed by the Working Group Nuclear Cardiology and Cardiac CT of the European Society of Cardiology and the European Council of Nuc. Eur Hear J. 2008;29(4):531-56.

303. Esposito A, Colantoni C, De Cobelli F, et al. Multidetector computed tomography for coronary stents imaging: High-voltage (140-KVP) prospective ecg-triggered versus standard-voltage (120-kvp) retrospective ecg-gated helical scanning. J Comput Assist Tomogr. 2013;37(3):395-401. doi:10.1097/RCT.0b013e3182873559.

304. Shiozaki AA, Senra T, Arteaga E, et al. Myocardial fibrosis detected by cardiac CT predicts ventricular fibrillation/ventricular tachycardia events in patients with hypertrophic cardiomyopathy.JCardiovascComputTomogr.2013;7(3):173-81.doi:10.1016/j.jcct.2013.04.002.

305. Rapezzi C, Quarta CC, Guidalotti PL, et al. Usefulness and limitations of 99mTc-3, 3-diphosphono-1, 2-propanodicarboxylic acid scintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathy. Eur J Nucl Med Mol Imaging. 2011;38(3):470-8. doi:10.1007/s00259-010-1642-7.

306. Rapezzi C, Quarta CC, Guidalotti PL, et al. Role of 99mTc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis. JACC Cardiovasc Imaging. 2011;4(6):659-70. doi:10.1016/j.jcmg.2011.03.016.

307. Dorbala S, Ando Y, Bokhari S, et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2-Evidence Base and Standardized Methods of Imaging. J Card Fail. 2019;25(11): e1-39. doi:10.1016/j.cardfail.2019.08.001.

308. Dorbala S, Ando Y, Bokhari S, et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2—Diagnostic Criteria and Appropriate Utilization. J Card Fail. 2019;25(11):85465. doi:10.1016/j.cardfail.2019.08.002.

309. Kawai C, Sakurai T, Fujiwara H, et al. Hypertrophic obstructive and non-obstructive cardiomyopathy in Japan. Diagnosis of the disease with special reference to endomyocardial catheter biopsy. Eur Hear J. 1983;4(1):121-5.

310. Scalone G, Niccoli G, Crea F. Editor’s ChoicePathophysiology, diagnosis and management of MINOCA: an update. Eur Hear Journal Acute Cardiovasc Care. 2019;8(1):54-62. doi:10.1177/2048872618782414.

311. Mitsutake R, Miura S, Sako H, et al. Usefulness of multi-detector row computed tomography for the management of percutaneous transluminal septal myocardial ablation in patient with hypertrophic obstructive cardiomyopathy. Int J Cardiol. 2008;129(2):61-3. doi:10.1016/j.ijcard.2007.06.132.

312. Okayama S, Uemura S, Soeda T, et al. Role of cardiac computed tomography in planning and evaluating percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy. J Cardiovasc Comput Tomogr. 2010;4(1):62-5. doi:10.1016/j.jcct.2009.10.004.

313. Villa ADM, Sammut E, Zarinabad N, et al. Microvascular ischemia in hypertrophic cardiomyopathy: New insights from high-resolution combined quantification of perfusion and late gadolinium enhancement. J Cardiovasc Magn Reson. 2016;18: Article number 4 (2015). doi:10.1186/s12968-016-0223-8.

314. Chen JM, Levin HR, Michler RE, et al. Reevaluating the significance of pulmonary hypertension before cardiac transplantation: Determination of optimal thresholds and quantification of the effect of reversibility on perioperative mortality. J Thorac Cardiovasc Surg. 1997;114(4):627-34. doi:10.1016/S0022-5223(97)70053-9.

315. Kato TS, Takayama H, Yoshizawa S, et al. Cardiac transplantation in patients with hypertrophic cardiomyopathy. Am J Cardiol. 2012;110(4):568-74. doi:10.1016/j.amjcard.2012.04.030.

316. Lindelöw B, Andersson B, Waagstein F, Bergh CH. High and low pulmonary vascular resistance in heart transplant candidates. A 5-year follow-up after heart transplantation shows continuous reduction in resistance and no difference in complication rate. Eur Heart J. 1999;20(2):148-56. doi:10.1053/euhj.1998.1155.

317. Maron MS, Kalsmith BM, Udelson JE, et al. Survival after cardiac transplantation in patients with hypertrophic cardiomyopathy. Circ Hear Fail. 2010;3(5):574-9. doi:10.1161/CIRCHEARTFAILURE.109.922872.

318. Mehra MR, Kobashigawa J, Starling R, et al. Listing Criteria for Heart Transplantation: International Society for Heart and Lung Transplantation Guidelines for the Care of Cardiac Transplant Candidates-2006. J Hear Lung Transplant. 2006;25(9):1024-42. doi:10.1016/j.healun.2006.06.008.

319. Torres MF, Perez-Villa F. Heart transplantation in patients with hypertrophic cardiomyopathy. Glob Cardiol Sci Pract. 2018;2018(3):32. doi:10.21542/gcsp.2018.32.

320. Blomström-Lundqvist C, Scheinman MM, Aliot EM, et al. ACC/AHA/ESC Guidelines for the Management of Patients with Supraventricular Arrhythmias — Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology. J Am Coll Cardiol. 2003;42(8):1493-531. doi:10.1016/j.jacc.2003.08.013.

321. Bokeria LA, Berseneva MI, Malenkov DA. Arrhythmogenic complications of hypertrophic cardiomyopathy. Annals of arrhythmology. 2010;7(3):62-9. (In Russ.) Бокерия Л. А., Берсенёва М. И., Маленков Д. А. Аритмогенные осложнения гипертрофической кардиомиопатии. Анналы аритмологии. 2010;7(3):62-9.

322. Muresan L, Cismaru G, Martins RP, et al. Recommendations for the use of electrophysiological study: Update 2018. Hell J Cardiol. 2019;60(2):82-100. doi:10.1016/j.hjc.2018.09.002.

323. Wang W, Lian Z, Rowin EJ, et al. Prognostic Implications of Nonsustained Ventricular Tachycardia in High-Risk Patients With Hypertrophic Cardiomyopathy. Circ Arrhythm Electrophysiol. 2017;10(3): e004604. doi:10.1161/CIRCEP.116.004604.

324. Inada K, Seiler J, Roberts-Thomson KC, et al. Substrate characterization and catheter ablation for monomorphic ventricular tachycardia in patients with apical hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol. 2011;22(1):41-8. doi:10.1111/j.15408167.2010.01875.x.

325. Lim KK, Maron BJ, Knight BP. Successful catheter ablation of hemodynamically unstable monomorphic ventricular tachycardia in a patient with hypertrophic cardiomyopathy and apical aneurysm. J Cardiovasc Electrophysiol. 2009;20(4):445-7. doi:10.1111/j.15408167.2008.01366.x.

326. Refaat MM, Hotait M, Tseng ZH. Utility of the exercise electrocardiogram testing in sudden cardiac death risk stratification. Ann Noninvasive Electrocardiol. 2014;19(4):311-8. doi:10.1111/anec.12191.

327. Yi G, Poloniecki J, Dickie S, et al. Can the Assessment of Dynamic QT Dispersion on Exercise Electrocardiogram Predict Sudden Cardiac Death in Hypertrophic Cardiomyopathy? Pacing Clin Electrophysiol. 2000;23(11Pt2):1953-6. doi:10.1111/j.1540-8159.2000.tb07060.x.

328. Nistri S, Olivotto I, Maron MS, et al. β-blockers for prevention of exercise-induced left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy. Am J Cardiol. 2012;110(5):715-9. doi:10.1016/j.amjcard.2012.04.051.

329. Rowin EJ, Maron BJ, Olivotto I, Maron MS. Role of Exercise Testing in Hypertrophic Cardiomyopathy. JACC Cardiovasc Imaging. 2017;10(11):1374-86. doi:10.1016/j.jcmg.2017.07.016.

330. Yalçin F, Muderrisoglu H, Korkmaz ME, et al. The effect of dobutamine stress on left ventricular outflow tract gradients in hypertensive patients with basal septal hypertrophy. Angiology. 2004;55(3):295-301. doi:10.1177/000331970405500309.

331. Mancini DM, Eisen H, Kussmaul W, et al. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation. 1991;83(3):778-86. doi:10.1161/01.CIR.83.3.778.

332. Sharma S, Elliott P, Whyte G, et al. Utility of cardiopulmonary exercise in the assessment of clinical determinants of functional capacity in hypertrophic cardiomyopathy. Am J Cardiol. 2000;86(2):162-8. doi:10.1016/S0002-9149(00)00854-7.

333. Колоскова Н. Н., Шаталов К. В., Бокерия Л. А. Определение пикового потребления кислорода: клиническое использование и перспективы. Креативная кардиология. 2014;2:20-8.

334. Coats CJ, Rantell K, Bartnik A, et al. Cardiopulmonary Exercise Testing and Prognosis in Hypertrophic Cardiomyopathy. Circ Hear Fail. 2015;8(6):1022-31. doi:10.1161/ CIRCHEARTFAILURE.114.002248.

335. Arena R, Owens DS, Arevalo J, et al. Ventilatory efficiency and resting hemodynamics in hypertrophic cardiomyopathy. Med Sci Sports Exerc. 2008;40(5):799-805. doi:10.1249/MSS.0b013e31816459a1.

336. Olivotto I, Maron BJ, Montereggi A, et al. Prognostic value of systemic blood pressure response during exercise in a community-based patient population with hypertrophic cardiomyopathy. J Am Coll Cardiol. 1999;33(7):2044-51. doi:10.1016/S0735-1097(99)00094-7.

337. Bennett MK, Gilotra NA, Harrington C, et al. Evaluation of the role of endomyocardial biopsy in 851 patients with unexplained heart failure from 2000-2009. Circ Hear Fail. 2013;6(4):676-84. doi:10.1161/CIRCHEARTFAILURE.112.000087.

338. Leone O, Veinot JP, Angelini A, et al. 2011 Consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology. Cardiovasc Pathol. 2012;21(4):245-74. doi:10.1016/j.carpath.2011.10.001.

339. Quarta CC, Gonzalez-Lopez E, Gilbertson JA, et al. Diagnostic Sensitivity of Abdominal Fat Aspiration in Cardiac Amyloidosis. Eur Hear J. 2017;38(24):1905-8.

340. Schönland SO, Hegenbart U, Bochtler T, et al. Immunohistochemistry in the classification of systemic forms of amyloidosis: A systematic investigation of 117 patients. Blood. 2012;119(2):488-93. doi:10.1182/blood-2011-06-358507.

341. Крылова Н. С., Хашиева Ф. М., Демкина А. Е. и др. Гипертрофическая кардиомиопатия и артериальная гипертензия: возможно ли сочетание? Сердце. Журнал для практикующих врачей. 2015;14(3(83)):164-9.

342. Полякова А. А., Гудкова А. Я., Крутиков А. Н. и др. Гипертрофическая кардиомиопатия в старшей возрастной группе: влияние факторов кардиометаболического риска и полиморфизма гена MADD. Артериальная гипертензия. 2018;24(1):29-40.

343. Abel ED, Litwin SE, Sweeney G. Cardiac remodeling in obesity. Physiol Rev. 2008:389-419. doi:10.1152/physrev.00017.2007.

344. Ommen SR, Lopez-Jimenez F. Obesity and hypertrophic cardiomyopathy: Chickens, eggs, and causality: Clinical skills remain the key to caring for patients. J Am Coll Cardiol. 2013;62(5):458-9. doi:10.1016/j.jacc.2013.03.063.

345. Olivotto I, Maron BJ, Tomberli B, et al. Obesity and its association to phenotype and clinical course in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2013;62(5):449-57. doi:10.1016/j.jacc.2013.03.062.

346. Di Tommaso L, Stassano P, Mannacio V, et al. Asymmetric septal hypertrophy in patients with severe aortic stenosis: The usefulness of associated septal myectomy. J Thorac Cardiovasc Surg. 2013;145(1):171-5. doi:10.1016/j.jtcvs.2011.10.096.

347. Dweck MR, Joshi S, Murigu T, et al. Left ventricular remodeling and hypertrophy in patients with aortic stenosis: Insights from cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2012;14(1):50. doi:10.1186/1532-429X-14-50.

348. Katayama M, Panse PM, Kendall CB, et al. Left ventricular septal hypertrophy in elderly patients with aortic stenosis. J Ultrasound Med. 2017;37(1):217-24. doi:10.1002/jum.14320.

349. Maron BJ, Edwards J, Epstein SE. Disproportionate ventricular septal thickening in patients with systemic hypertension. Chest. 1978;73(4):466-70. doi:10.1378/chest.73.4.466.

350. Rodrigues JCL, Amadu AM, Dastidar AG, et al. Prevalence and Predictors of Asymmetric Hypertensive Heart Disease: Insights From Cardiac and Aortic Function With Cardiovascular Magnetic Resonance. Eur Hear J Cardiovasc Imaging. 2016;17(12):1405-13.

351. Tuseth N, Cramariuc D, Rieck ÅE, et al. Asymmetric septal hypertrophy — A marker of hypertension in aortic stenosis (a SEAS substudy). Blood Press. 2010;19(3):140-4. doi:10.3109/08037051.2010.481816.

352. Van Straten AHM, Soliman Hamad MA, Peels KCH, et al. Increased septum wall thickness in patients undergoing aortic valve replacement predicts worse late survival. Ann Thorac Surg. 2012;94(1):66-71. doi:10.1016/j.athoracsur.2012.03.027.

353. Shapiro LM, Howat AP, Crean PA, Westgate CJ. An echocardiographic study of localized subaortic hypertrophy. Eur Heart J. 1986;7(2):127-32. doi:10.1093/oxfordjournals.eurheartj.a062034.

354. Gutiérrez-Barrios A, Camacho-Jurado F, Díaz-Retamino E, et al. Invasive assessment of coronary microvascular dysfunction in hypertrophic cardiomyopathy: The index of microvascular resistance. Cardiovasc Revascularization Med. 2015;16(7):426-8. doi:10.1016/j.carrev.2015.06.008.

355. Ismail TF, Hsu LY, Greve AM, et al. Coronary microvascular ischemia in hypertrophic cardiomyopathy — A pixel-wise quantitative cardiovascular magnetic resonance perfusion study. J Cardiovasc Magn Reson. 2014;16(1):49. doi:10.1186/s12968-014-0049-1.

356. Olivotto I, Girolami F, Sciagr R, et al. Microvascular function is selectively impaired in patients with hypertrophic cardiomyopathy and sarcomere myofilament gene mutations. J Am Coll Cardiol. 2011;58(8):839-48. doi:10.1016/j.jacc.2011.05.018.

357. Raissuni Z, Doghmi N, Mousseaux E, et al. Hypertrophic cardiomyopathy mimicking STEMI: The role of cardiac magnetic resonance imaging in the detection of microvascular coronary dysfunction. Diagn Interv Imaging. 2014;95(11):1111-2. doi:10.1016/j.diii.2013.12.020.

358. Timmer SAJ, Knaapen P. Coronary Microvascular Function, Myocardial Metabolism, and Energetics in Hypertrophic Cardiomyopathy: Insights From Positron Emission Tomography. Eur Hear J Cardiovasc Imaging. 2013;14(2):95-101.

359. Zhang YD, Li M, Qi L, et al. Hypertrophic cardiomyopathy: Cardiac structural and microvascular abnormalities as evaluated with multi-parametric MRI. Eur J Radiol. 2015;84(8):1480-6. doi:10.1016/j.ejrad.2015.04.028.

360. Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Circulation. 2006;114(10): e385-484. doi:10.1161/CIRCULATIONAHA.106.178233.

361. Basavarajaiah S, Wilson M, Whyte G, et al. Prevalence of Hypertrophic Cardiomyopathy in Highly Trained Athletes. Relevance to Pre-Participation Screening. J Am Coll Cardiol. 2008;51(10):1033-9. doi:10.1016/j.jacc.2007.10.055.

362. Malhotra A, Sharma S. Hypertrophic cardiomyopathy in athletes. Eur Cardiol Rev. 2017;12(2):80-2. doi:10.15420/ecr.2017:12:1.

363. Pelliccia A, Corrado D, Bjãrnstad HH, et al. Recommendations for participation in competitive sport and leisure-time physical activity in individuals with cardiomyopathies, myocarditis and pericarditis. Eur J Prev Cardiol. 2006;13(6):876-85. doi:10.1097/01.hjr.0000238393.96975.32.

364. Liebregts M, Faber L, Jensen MK, et al. Validation of the HCM Risk-SCD model in patients with hypertrophic cardiomyopathy following alcohol septal ablation. Europace. 2018;20(FI2):198-203. doi:10.1093/europace/eux251.

365. Vriesendorp PA, Schinkel AFL, Liebregts M, et al. Validation of the 2014 European Society of Cardiology Guidelines Risk Prediction Model for the Primary Prevention of Sudden Cardiac Death in Hypertrophic Cardiomyopathy. Circ Arrhythmia Electrophysiol. 2015;8(4):829-35. doi:10.1161/CIRCEP.114.002553.

366. Tsuda T, Hayashi K, Konno T, et al. J Waves for Predicting Cardiac Events in Hypertrophic Cardiomyopathy. JACC Clin Electrophysiol. 2017;3(10):1136-42. doi:10.1016/J. JACEP.2017.03.010.

367. Veselka J, Liebregts M, Cooper R, et al. Prediction of Sudden Cardiac Arrest After Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy: ASA-SCARRE Risk Score. Am J Cardiol. 2022;184:120-6. doi:10.1016/J.AMJCARD.2022.08.028.

368. Spoladore R, Maron MS, D’Amato R, et al. Pharmacological Treatment Options for Hypertrophic Cardiomyopathy: High Time for Evidence. Eur Hear J. 2012;33(14):1724-33.

369. Patten M, Pecha S, Aydin A. Atrial Fibrillation in Hypertrophic Cardiomyopathy: Diagnosis and Considerations for Management. J Atr Fibrillation. 2018;10(5):1556.

370. Rujirachun P, Charoenngam N, Wattanachayakul P, et al. Efficacy and safety of direct oral anticoagulants (DOACs) versus vitamin K antagonist (VKA) among patients with atrial fibrillation and hypertrophic cardiomyopathy: a systematic review and meta-analysis. Acta Cardiol. 2019;75(8):724-31. doi:10.1080/00015385.2019.1668113.

371. Maron BJ, Casey SA, Olivotto I, et al. Clinical Course and Quality of Life in High-Risk Patients With Hypertrophic Cardiomyopathy and Implantable Cardioverter-Defibrillators. Circ Arrhythm Electrophysiol. 2018;11(4). doi:10.1161/CIRCEP.117.005820.

372. Klopotowski M, Kukula K, Jamiolkowski J, et al. Sudden Cardiac Death Risk over Time in HCM Patients with Implantable Cardioverter-Defibrillator. J Clin Med. 2022;11(6). doi:10.3390/JCM11061633.

373. Lambiase PD, Barr C, Theuns DAMJ, et al. Worldwide Experience With a Totally Subcutaneous Implantable Defibrillator: Early Results From the EFFORTLESS S-ICD Registry. Eur Hear J. 2014;35(25):1657-65.

374. Dearani JA, Ommen SR, Gersh BJ, et al. Surgery Insight: Septal myectomy for obstructive hypertrophic cardiomyopathy — The Mayo Clinic experience. Nat Clin Pract Cardiovasc Med. 2007;4(9):503-12. doi:10.1038/ncpcardio0965.

375. Leonardi RA, Kransdorf EP, Simel DL, Wang A. Meta-analyses of septal reduction therapies for obstructive hypertrophic cardiomyopathy comparative rates of overall mortality and sudden cardiac death after treatment. Circ Cardiovasc Interv. 2010;3(2):97-104. doi:10.1161/CIRCINTERVENTIONS.109.916676.

376. Afanasyev AV, Bogachev-Prokophiev AV, Ovcharov MA, et al. Single-Centre Experience of Surgical Myectomy for Hypertrophic Obstructive Cardiomyopathy. Hear Lung Circ. 2019;29(6):949-55. doi:10.1016/j.hlc.2019.07.009.

377. Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC). Rev Esp Cardiol (Engl Ed). 2022;75(5):429. doi:10.1016/ J.REC.2022.04.003.

378. Ammirati E, Contri R, Coppini R, et al. Pharmacological treatment of hypertrophic cardiomyopathy: current practice and novel perspectives. Eur J Heart Fail. 2016;18(9):1106-18. doi:10.1002/ejhf.541.

379. Udelson JE, Bonow RO, O’Gara PT, et al. Verapamil prevents silent myocardial perfusion abnormalities during exercise in asymptomatic patients with hypertrophic cardiomyopathy. Circulation. 1989;79(5):1052-60. doi:10.1161/01.CIR.79.5.1052.

380. Sherrid MV, Shetty A, Winson G, et al. Treatment of obstructive hypertrophic cardiomyopathy symptoms and gradient resistant to first-line therapy with β-blockade or verapamil. Circ Hear Fail. 2013;6(4):694-702. doi:10.1161/CIRCHEARTFAILURE.112.000122.

381. Sherrid MV. Drug Therapy for Hypertrophic Cardiomypathy: Physiology and Practice. Curr Cardiol Rev. 2016;12(1):52-65. doi:10.2174/1573403x1201160126125403.

382. Monda E, Lioncino M, Palmiero G, et al. Bisoprolol for treatment of symptomatic patients with obstructive hypertrophic cardiomyopathy. The BASIC (bisoprolol AS therapy in hypertrophic cardiomyopathy) study. Int J Cardiol. 2022;354:22-8. doi:10.1016/J.IJCARD.2022.03.013.

383. Dybro AM, Rasmussen TB, Nielsen RR, et al. Metoprolol Improves Left Ventricular Longitudinal Strain at Rest and during Exercise in Obstructive Hypertrophic Cardiomyopathy. J Am Soc Echocardiogr. 2023;36(2):196-204. doi:10.1016/J.ECHO.2022.09.008.

384. Toshima H, Koga Y, Nagata H, et al. Comparable effects of oral diltiazem and verapamil in the treatment of hypertrophic cardiomyopathy. Double-blind crossover study. Jpn Hear J. 1986;27(5):701-15. doi:10.1536/ihj.27.701.

385. Bonow RO, Dilsizian V, Rosing DR, et al. Verapamil-induced improvement in left ventricular diastolic filling and increased exercise tolerance in patients with hypertrophic cardiomyopathy: Shortand long-term effects. Circulation. 1985;72(4):853-64. doi:10.1161/01. CIR.72.4.853.

386. Tezuka A, Higo K, Nakamukae Y, et al. Bisoprolol successfully improved the intraventricular pressure gradient in a patient with midventricular obstructive hypertrophic cardiomyopathy with an apex aneurysm due to apical myocardial damage. Intern Med. 2019;58(4): 535-9. doi:10.2169/internalmedicine.0997-18.

387. Said SM, Schaff HV, Abel MD, Dearani JA. Transapical approach for apical myectomy and relief of midventricular obstruction in hypertrophic cardiomyopathy. J Card Surg. 2012;27(4):443-8. doi:10.1111/j.1540-8191.2012.01475.x.

388. Богачев-Прокофьев А. В., Железнев С. И., Фоменко М.С. и др. Эффективность расширенной миоэктомии у пациентов с желудочковой обструкцией при гипертрофической кардиомиопатии. Кардиология. 2017;57(5):38-43.

389. Nguyen A, Schaff HV. Surgical Myectomy: Subaortic, Midventricular, and Apical. Cardiol Clin. 2019;37(1):95-104. doi:10.1016/J.CCL.2018.08.006.

390. Schaff HV, Brown ML, Dearani JA, et al. Apical myectomy: a new surgical technique for management of severely symptomatic patients with apical hypertrophic cardiomyopathy. J Thorac Cardiovasc Surg. 2010;139(3):634-40. doi:10.1016/J.JTCVS.2009.07.079.

391. Batzner A, Schäfers H-J, Borisov KV, Seggewiß H. Hypertrophic Obstructive Cardiomyopathy. Dtsch Arztebl Int. 2019;116(4):47-53. doi:10.3238/ARZTEBL.2019.0047.

392. Epstein SE, Rosing DR. Verapamil: Its potential for causing serious complications in patients with hypertrophic cardiomyopathy. Circulation. 1981;64(3):437-41. doi:10.1161/01.CIR.64.3.437.

393. Maron BJ, Rowin EJ, Casey SA, et al. Hypertrophic Cardiomyopathy in Adulthood Associated With Low Cardiovascular Mortality With Contemporary Management Strategies. J Am Coll Cardiol. 2015;65(18):1915-28. doi:10.1016/J.JACC.2015.02.061.

394. Charron P, Elliott PM, Gimeno JR, et al. The Cardiomyopathy Registry of the EURObservational Research Programme of the European Society of Cardiology: baseline data and contemporary management of adult patients with cardiomyopathies. Eur Heart J. 2018;39(20):1784-93. doi:10.1093/EURHEARTJ/EHX819.

395. Olivotto I, Cecchi F, Casey SA, et al. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation. 2001;104(21):2517-24. doi:10.1161/hc4601.097997.

396. Kuperstein R, Klempfner R, Ofek E, et al. De novo mitral regurgitation as a cause of heart failure exacerbation in patients with hypertrophic cardiomyopathy. Int J Cardiol. 2018;252:122-7. doi:10.1016/J.IJCARD.2017.11.060.

397. Subramanian M, Sravani V, Krishna SP, et al. Efficacy of SGLT2 Inhibitors in Patients With Diabetes and Nonobstructive Hypertrophic Cardiomyopathy. Am J Cardiol. 2023;188: 80-6. doi:10.1016/J.AMJCARD.2022.10.054.

398. Maron MS, Chan RH, Kapur NK, et al. Effect of Spironolactone on Myocardial Fibrosis and Other Clinical Variables in Patients with Hypertrophic Cardiomyopathy. Am J Med. 2018;131(7):837-41. doi:10.1016/j.amjmed.2018.02.025.

399. Olivotto I, Oreziak A, Barriales-Villa R, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, doubleblind, placebo-controlled, phase 3 trial. Lancet (London, England). 2020;396(10253):7569. doi:10.1016/S0140-6736(20)31792-X.

400. Pelliccia F, Cecchi F, Olivotto I, Camici PG. Microvascular Dysfunction in Hypertrophic Cardiomyopathy. J Clin Med. 2022;11(21):6560. doi:10.3390/JCM11216560.

401. Cannon RO, Rosing DR, Maron BJ, et al. Myocardial ischemia in patients with hypertrophic cardiomyopathy: contribution of inadequate vasodilator reserve and elevated left ventricular filling pressures. Circulation. 1985;71(2):234-43. doi:10.1161/01.CIR.71.2.234.

402. Krams R, Kofflard MJM, Duncker DJ, et al. Decreased coronary flow reserve in hypertrophic cardiomyopathy is related to remodeling of the coronary microcirculation. Circulation. 1998;97(3):230-3. doi:10.1161/01.CIR.97.3.230.

403. Shariat M, Thavendiranathan P, Nguyen E, et al. Utility of coronary CT angiography in outpatients with hypertrophic cardiomyopathy presenting with angina symptoms. J Cardiovasc Comput Tomogr. 2014;8(6):429-37. doi:10.1016/J.JCCT.2014.09.007.

404. van der Velde N, Huurman R, Yamasaki Y, et al. Frequency and Significance of Coronary Artery Disease and Myocardial Bridging in Patients With Hypertrophic Cardiomyopathy. Am J Cardiol. 2020;125(9):1404-12. doi:10.1016/J.AMJCARD.2020.02.002.

405. Dias A, Núñez Gil IJ, Santoro F, et al. Takotsubo syndrome: State-of-the-art review by an expert panel — Part 2. Cardiovasc Revasc Med. 2019;20(2):153-66. doi:10.1016/J.CARREV.2018.11.016.

406. Pelliccia F, Limongelli G, Autore C, et al. Sex-related differences in cardiomyopathies. Int J Cardiol. 2019;286:239-43. doi:10.1016/J.IJCARD.2018.10.091.

407. Crea F, Camici PG, Merz CNB. Coronary microvascular dysfunction: an update. Eur Heart J. 2014;35(17):1101-11. doi:10.1093/EURHEARTJ/EHT513.

408. Puwanant S, Trongtorsak A, Wanlapakorn C, et al. Acute coronary syndrome with nonobstructive coronary arteries (ACS-NOCA) in patients with hypertrophic cardiomyopathy. BMC Cardiovasc Disord. 2021;21(1):556. doi:10.1186/S12872-021-02373-Z.

409. Российское кардиологическое общество (РКО). Стабильная ишемическая болезнь сердца. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(11):4076. doi:10.15829/29/1560-4071-2020-4076.

410. Kunadian V, Chieffo A, Camici PG, et al. An EAPCI Expert Consensus Document on Ischaemia with Non-Obstructive Coronary Arteries in Collaboration with European Society of Cardiology Working Group on Coronary Pathophysiology & Microcirculation Endorsed by Coronary Vasomotor Disorders International Study Group. Eur Heart J. 2020;41(37):3504-20. doi:10.1093/EURHEARTJ/EHAA503.

411. Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407-77. doi:10.1093/EURHEARTJ/EHZ425.

412. Dybro AM, Rasmussen TB, Nielsen RR, et al. Randomized Trial of Metoprolol in Patients With Obstructive Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2021;78(25):2505-17. doi:10.1016/J.JACC.2021.07.065.

413. Wilmshurst PT, Thompson DS, Juul SM, et al. Effects of verapamil on haemodynamic function and myocardial metabolism in patients with hypertrophic cardiomyopathy. Heart. 1986;56(6):544-53. doi:10.1136/hrt.56.6.544.

414. Petkow Dimitrow P, Krzanowski M, Nizankowski R, et al. Effect of verapamil on systolic and diastolic coronary blood flow velocity in asymptomatic and mildly symptomatic patients with hypertrophic cardiomyopathy. Heart. 2000;83(3):262-6. doi:10.1136/HEART.83.3.262.

415. Mengesha HG, Weldearegawi B, Petrucka P, et al. Effect of ivabradine on cardiovascular outcomes in patients with stable angina: meta-analysis of randomized clinical trials. BMC Cardiovasc Disord. 2017;17(1):105. doi:10.1186/S12872-017-0540-3.

416. Gupta T, Harikrishnan P, Kolte D, et al. Outcomes of acute myocardial infarction in patients with hypertrophic cardiomyopathy. Am J Med. 2015;128(8):879-87.e1. doi:10.1016/J.AMJMED.2015.02.025.

417. Thygesen K, Alpert JS, Jaffe AS, et al. Fourth Universal Definition of Myocardial Infarction (2018). Circulation. 2018;138(20): e618-51. doi:10.1161/CIR.0000000000000617.

418. Yang YJ, Fan CM, Yuan JQ, et al. Long-term survival after acute myocardial infarction in patients with hypertrophic cardiomyopathy. Clin Cardiol. 2017;40(1):26-31. doi:10.1002/CLC.22601.

419. Tamis-Holland JE, Jneid H, Reynolds HR, et al. Contemporary Diagnosis and Management of Patients With Myocardial Infarction in the Absence of Obstructive Coronary Artery Disease: A Scientific Statement From the American Heart Association. Circulation. 2019;139(18): E891-908. doi:10.1161/CIR.0000000000000670.

420. Российское кардиологическое общество (РКО). Острый инфаркт миокарда с подъемом сегмента ST электрокардиограммы. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(11):4103. doi:10.15829/29/15604071-2020-4103.

421. Барбараш О. Л., Дупляков Д. В., Затейщиков Д. А. и др. Острый коронарный синдром без подъема сегмента ST электрокардиограммы. Клинические рекомендации 2020. Российский кардиологический журнал. 2021;26(4):4449. doi:10.15829/1560-4071-2021-4449.

422. De Filippo O, Russo C, Manai R, et al. Impact of secondary prevention medical therapies on outcomes of patients suffering from Myocardial Infarction with NonObstructive Coronary Artery disease (MINOCA): A meta-analysis. Int J Cardiol. 2022;368(1):1-9. doi:10.1016/J.IJCARD.2022.08.034.

423. Samaras A, Papazoglou AS, Balomenakis C, et al. Prognostic impact of secondary prevention medical therapy following myocardial infarction with non-obstructive coronary arteries: a Bayesian and frequentist meta-analysis. Eur Hear J Open. 2022;2(6):077. doi:10.1093/EHJOPEN/OEAC077.

424. Abdu FA, Liu L, Mohammed AQ, et al. Effect of Secondary Prevention Medication on the Prognosis in Patients With Myocardial Infarction With Nonobstructive Coronary Artery Disease. J Cardiovasc Pharmacol. 2020;76(6):678-83. doi:10.1097/FJC. 0000000000000918.

425. Paolisso P, Bergamaschi L, Saturi G, et al. Secondary Prevention Medical Therapy and Outcomes in Patients With Myocardial Infarction With Non-Obstructive Coronary Artery Disease. Front Pharmacol. 2020;10:1606. doi:10.3389/FPHAR.2019.01606.

426. Bossard M, Gao P, Boden W, et al. Antiplatelet therapy in patients with myocardial infarction without obstructive coronary artery disease. Heart. 2021;107(21):1739-47. doi:10.1136/HEARTJNL-2020-318045.

427. Аверков О. В., Арутюнян Г. К., Дупляков Д. В. и др. Острый инфаркт миокарда без подъема сегмента ST электрокардиограммы. Клинические рекомендации 2024. Российский кардиологический журнал. 2025;30(5):6319. doi:10.15829/1560-4071-2025-6319. EDN CXJUIB.

428. Кобалава Ж. Д., Конради А. О., Недогода С. В. и др. Артериальная гипертензия у взрослых. Клинические рекомендации 2024. Российский кардиологический журнал. 2024;29(9):6117. doi:10.15829/1560-4071-2024-6117. EDN GUEWLU.

429. Rosing DR, Idänpään-Heikkilä U, Maron BJ, et al. Use of calcium-channel blocking drugs in hypertrophic cardiomyopathy. Am J Cardiol. 1985;55(3). doi:10.1016/00029149(85)90630-7.

430. Betocchi S, Piscione F, Losi MA, et al. Effects of diltiazem on left ventricular systolic and diastolic function in hypertrophic cardiomyopathy. Am J Cardiol. 1996;78(4):451-7. doi:10.1016/S0002-9149(96)00336-0.

431. López-Sendón J, Swedberg K, McMurray J, et al. Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J. 2004;25(15):1341-62. doi:10.1016/J. EHJ.2004.06.002.

432. Maron BJ. Hypertrophic Cardiomyopathy: A Systematic Review. JAMA. 2002;287(10): 1308-20.

433. Maron BJ, Olivotto I, Bellone P, et al. Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2002;39(2):301-7. doi:10.1016/S07351097(01)01727-2.

434. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart R. J Am Coll Cardiol. 2019;74(1):104-32. doi:10.1016/J.JACC.2019.01.011.

435. Di Cori A, Lilli A, Zucchelli G, Zaca V. Role of cardiac electronic implantable device in the stratification and management of embolic risk of silent atrial fibrillation: are all atrial fibrillations created equal? Expert Rev Cardiovasc Ther. 2018;16(3):175-81. doi:10.1080/14779072.2018.1438267.

436. Camm CF, Camm AJ. Atrial fibrillation and anticoagulation in hypertrophic cardiomyopathy. Arrhythmia Electrophysiol Rev. 2017;6(2):63-8. doi:10.15420/aer.2017.4.2.

437. Miller CAS, Maron MS, Estes NAM, et al. Safety, Side Effects and Relative Efficacy of Medications for Rhythm Control of Atrial Fibrillation in Hypertrophic Cardiomyopathy. Am J Cardiol. 2019;123(11):1859-62. doi:10.1016/j.amjcard.2019.02.051.

438. Гринева Е. Н., Цой У. А., Каронова Т. Л. и др. Проект федеральных клинических рекомендаций по диагностике и лечению амиодарон-индуцированной дисфункции щитовидной железы. Клиническая и экспериментальная тиреоидология. 2020;16(2):12-24. doi:10.14341/KET12693.

439. Bartalena L, Bogazzi F, Chiovato L, et al. 2018 European Thyroid Association (ETA) Guidelines for the Management of Amiodarone-Associated Thyroid Dysfunction. Eur Thyroid J. 2018;7(2):55-66. doi:10.1159/000486957.

440. Theodoraki A, Vanderpump MPJ. Thyrotoxicosis associated with the use of amiodarone: the utility of ultrasound in patient management. Clin Endocrinol (Oxf). 2016;84(2):172-6. doi:10.1111/CEN.12988.

441. Zhou YY, He W, Zhou YY, Zhu W. Non-vitamin K antagonist oral anticoagulants in patients with hypertrophic cardiomyopathy and atrial fibrillation: a systematic review and metaanalysis. J Thromb Thrombolysis. 2020;50(2):311-7. doi:10.1007/s11239-019-02008-3.

442. Lee HJ, Kim HK, Jung JH, et al. Novel Oral Anticoagulants for Primary Stroke Prevention in Hypertrophic Cardiomyopathy Patients with Atrial Fibrillation. Stroke. 2019;50(9): 2582-6. doi:10.1161/STROKEAHA.119.026048.

443. Dominguez F, Climent V, Zorio E, et al. Direct oral anticoagulants in patients with hypertrophic cardiomyopathy and atrial fibrillation. Int J Cardiol. 2017;248:232-8. doi:10.1016/j.ijcard.2017.08.010.

444. Li B, Sun C, Qin F, et al. Could direct oral anticoagulants be an alternative to vitamin K antagonists in patients with hypertrophic cardiomyopathy and atrial fibrillation? Int J Cardiol. 2018;256:39. doi:10.1016/j.ijcard.2017.10.113.

445. Lozier MR, Sanchez AM, Lee JJ, et al. Thromboembolic outcomes of different anticoagulation strategies for patients with atrial fibrillation in the setting of hypertrophic cardiomyopathy: A systematic review. J Atr Fibrillation. 2019;12(4):2207. doi:10.4022/jafib.2207.

446. Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The euro heart survey. Chest. 2010;138(5):1093-100. doi:10.1378/chest.10-0134.

447. Veselka J, Faber L, Liebregts M, et al. Shortand long-term outcomes of alcohol septal ablation for hypertrophic obstructive cardiomyopathy in patients with mild left ventricular hypertrophy: a propensity score matching analysis. Eur Hear J. 2019;40(21):1681-7.

448. Каштанов М. Г., Чернышев С. Д., Кардапольцев Л. В. и др. Этаноловая септальная аблация в лечении обструктивной гипертрофической кардиомиопатии: отбор пациентов и рациональность ее применения. Патология кровообращения и кардиохирургия. 2017;21(1):104-16.

449. Ommen SR, Maron BJ, Olivotto I, et al. Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005;46(3):470-6. doi:10.1016/J.JACC.2005.02.090.

450. Mitra A, Ghosh RK, Bandyopadhyay D, et al. Significance of Pulmonary Hypertension in Hypertrophic Cardiomyopathy. Curr Probl Cardiol. 2020;45(6):00398. doi:10.1016/J.CPCARDIOL.2018.10.002.

451. Desai MY, Bhonsale A, Patel P, et al. Exercise echocardiography in asymptomatic HCM: exercise capacity, and not LV outflow tract gradient predicts long-term outcomes. JACC Cardiovasc Imaging. 2014;7(1):26-36. doi:10.1016/J.JCMG.2013.08.010.

452. Nguyen A, Schaff HV, Nishimura RA, et al. Determinants of Reverse Remodeling of the Left Atrium After Transaortic Myectomy. Ann Thorac Surg. 2018;106(2):447-53. doi:10.1016/j.athoracsur.2018.03.039.

453. Finocchiaro G, Haddad F, Kobayashi Y, et al. Impact of Septal Reduction on Left Atrial Size and Diastole in Hypertrophic Cardiomyopathy. Echocardiography. 2016;33(5):686-94. doi:10.1111/ECHO.13158.

454. Blackshear JL, Stark ME, Agnew RC, et al. Remission of recurrent gastrointestinal bleeding after septal reduction therapy in patients with hypertrophic obstructive cardiomyopathyassociated acquired von Willebrand syndrome. J Thromb Haemost. 2015;13(2):191-6. doi:10.1111/JTH.12780.

455. Desai MY, Smedira NG, Dhillon A, et al. Prediction of sudden death risk in obstructive hypertrophic cardiomyopathy: Potential for refinement of current criteria. J Thorac Cardiovasc Surg. 2018;156(2):750-759.e3. doi:10.1016/J.JTCVS.2018.03.150.

456. McLeod CJ, Ommen SR, Ackerman MJ, et al. Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive hypertrophic cardiomyopathy. Eur Heart J. 2007;28(21):2583-8. doi:10.1093/EURHEARTJ/EHM117.

457. Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC Focused Update of the 2014 AHA/ ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2017;70(2):252-89. doi:10.1016/J.JACC.2017.03.011.

458. Sorajja P, Nishimura RA, Gersh BJ, et al. Outcome of mildly symptomatic or asymptomatic obstructive hypertrophic cardiomyopathy: a long-term follow-up study. J Am Coll Cardiol. 2009;54(3):234-41. doi:10.1016/J.JACC.2009.01.079.

459. Ball W, Ivanov J, Rakowski H, et al. Long-term survival in patients with resting obstructive hypertrophic cardiomyopathy comparison of conservative versus invasive treatment. J Am Coll Cardiol. 2011;58(22):2313-21. doi:10.1016/J.JACC.2011.08.040.

460. Mestres CA, Bartel T, Sorgente A, et al. Hypertrophic Obstructive Cardiomyopathy: What, When, Why, for Whom? Eur J Cardiothorac Surg. 2018;53(4):700-7.

461. Хитрова М. Э., Бокерия Л. А., Берсенева М. И. и др. Метаанализ результатов хирургического лечения гипертрофической обструктивной кардиомиопатии. Креативная кардиология. 2017;11(4):337-47. doi:10.24022/19973187-2017-11-4-337-347.

462. Veselka J, Jensen MK, Liebregts M, et al. Long-term clinical outcome after alcohol septal ablation for obstructive hypertrophic cardiomyopathy: Results from the Euro-ASA registry. Eur Heart J. 2016;37(19):1517-23. doi:10.1093/eurheartj/ehv693.

463. Bogachev-Prokophiev A, Afanasyev A, Zheleznev S, et al. Mitral Valve Repair or Replacement in Hypertrophic Obstructive Cardiomyopathy: A Prospective Randomized Study. Interact Cardiovasc Thorac Surg. 2017;25(3):356-62. doi:10.1093/ICVTS/IVX152.

464. Bogachev-Prokophiev A, Afanasyev AV, Zheleznev S, et al. Septal Myectomy With Vs Without Subvalvular Apparatus Intervention in Patients With Hypertrophic Obstructive Cardiomyopathy: A Prospective Randomized Study. Semin Thorac Cardiovasc Surg. 2019;31(3):424-31. doi:10.1053/j.semtcvs.2019.01.011.

465. Afanasyev A, Bogachev-Prokophiev A, Lenko E, et al. Myectomy With Mitral Valve Repair Versus Replacement in Adult Patients With Hypertrophic Obstructive Cardiomyopathy: A Systematic Review and Meta-Analysis. Interact Cardiovasc Thorac Surg. 2019;28(3):46572. doi:10.1093/ICVTS/IVY269.

466. Гурщенков А. В., Сухова И. В., Зайцев В. В. и др. Пятилетний опыт использования мобилизации сердца при септальной миоэктомии. Кардиология и сердечно-сосудистая хирургия. 2018;11(4):54-8.

467. Morrow AG, Reitz BA, Epstein SE, et al. Operative treatment in hypertrophic subaortic stenosis. Techniques, and the results of pre and postoperative assessments in 83 patients. Circulation. 1975;52(1):88-102. doi:10.1161/01.CIR.52.1.88.

468. Messmer BJ, Klues HG, Reith S, et al. Hypertrophic obstructive cardiomyopathy. Adv Card Surg. 1998;10:245-70.

469. Хитрова М. Э., Бокерия Л. А., Берсенева М. И., Маленков Д. А. Клинические случаи успешного хирургического лечения гипертрофической обструктивной кардиомиопатии с митральной недостаточностью и samсиндромом, выполненного методом миэктомии межжелудочковой перегородки из правого желудочка. Бюллетень НЦССХ им. А. Н. Бакулева РАМН. 2017;18(6):609-17.

470. Sun D, Schaff HV, Nishimura RA, et al. Transapical Septal Myectomy for Hypertrophic Cardiomyopathy With Midventricular Obstruction. Ann Thorac Surg. 2021;111(3):836-44. doi:10.1016/J.ATHORACSUR.2020.05.182.

471. Tang Y, Song Y, Duan F, et al. Extended myectomy for hypertrophic obstructive cardiomyopathy patients with midventricular obstruction. Eur J Cardiothorac Surg. 2018;54(5):875-83. doi:10.1093/EJCTS/EZY203.

472. Borisov KV. Right ventricle myectomy. Ann Cardiothorac Surg. 2017;6(4):402-9. doi:10.21037/acs.2017.07.10.

473. Wehman B, Ghoreishi M, Foster N, et al. Transmitral Septal Myectomy for Hypertrophic Obstructive Cardiomyopathy. Ann Thorac Surg. 2018;105(4):1102-8. doi:10.1016/j.athoracsur.2017.10.045.

474. Бокерия Л. А. Гипертрофическая обструктивная кардиомиопатия. Анналы хирургии. 2013;5:5-14.

475. Takahashi J, Wakamatsu Y, Okude J, et al. Septal Myectomy, Papillary Muscle Resection, and Mitral Valve Replacement for Hypertrophic Obstructive Cardiomyopathy: A Case Report. Ann Thorac Cardiovasc Surg. 2008;14(4):258-62.

476. Holst KA, Hanson KT, Ommen SR, et al. Septal Myectomy in Hypertrophic Cardiomyopathy: National Outcomes of Concomitant Mitral Surgery. Mayo Clin Proc. 2019;94(1): 66-73. doi:10.1016/J.MAYOCP.2018.07.022.

477. Hong JH, Schaff HV, Nishimura RA, et al. Mitral Regurgitation in Patients With Hypertrophic Obstructive Cardiomyopathy: Implications for Concomitant Valve Procedures. J Am Coll Cardiol. 2016;68(14):1497-504. doi:10.1016/J.JACC.2016.07.735.

478. Stassano P, Tommaso LDi, Triggiani D, et al. Mitral Valve Replacement and Limited Myectomy for Hypertrophic Obstructive Cardiomyopathy: A 25-Year Follow-Up. Texas Hear Inst J. 2004;31(2):137-42.

479. Afanasyev AV, Bogachev-Prokophiev AV, Zheleznev SI, et al. Edge-to-Edge Repair Versus Secondary Cord Cutting During Septal Myectomy in Patients With Hypertrophic Obstructive Cardiomyopathy: A Pilot Randomised Study. Heart Lung Circ. 2021;30(3):43845. doi:10.1016/J.HLC.2020.05.106.

480. Ferrazzi P, Spirito P, Iacovoni A, et al. Transaortic Chordal Cutting: Mitral Valve Repair for Obstructive Hypertrophic Cardiomyopathy With Mild Septal Hypertrophy. J Am Coll Cardiol. 2015;66(15):1687-96. doi:10.1016/J.JACC.2015.07.069.

481. Nguyen A, Schaff HV, Nishimura RA, et al. Apical myectomy for patients with hypertrophic cardiomyopathy and advanced heart failure. J Thorac Cardiovasc Surg. 2020;159(1):14552. doi:10.1016/J.JTCVS.2019.03.088.

482. Afanasyev A, Bogachev-Prokophiev A, Zheleznev S, et al. Transapical Approach to Septal Myectomy for Hypertrophic Cardiomyopathy. Life (Basel, Switzerland). 2024;14(1):125. doi:10.3390/LIFE14010125.

483. Афанасьев А. В., Богачев-Прокофьев А. В., Кирилова В. С. и др. Трансапикальная миоэктомия как альтернатива трансплантации сердца у пациента с апикальной гипертрофической кардиомиопатией. Клиническая и экспериментальная хирургия, журнал им. акад. Б. В. Петровского. 2024;12(1):127-34.

484. Boll G, Rowin EJ, Maron BJ, et al. Efficacy of Combined Cox-Maze IV and Ventricular Septal Myectomy for Treatment of Atrial Fibrillation in Patients With Obstructive Hypertrophic Cardiomyopathy. Am J Cardiol. 2020;125(1):120-6. doi:10.1016/J.AMJCARD.2019.09.029.

485. Bogachev-Prokophiev AV, Afanasyev AV, Zheleznev SI, et al. Concomitant ablation for atrial fibrillation during septal myectomy in patients with hypertrophic obstructive cardiomyopathy. J Thorac Cardiovasc Surg. 2018;155(4):1536-42.e2. doi:10.1016/ j.jtcvs.2017.08.063.

486. Prinz C, Schwarz M, Ilic I, et al. Myocardial Fibrosis Severity on Cardiac Magnetic Resonance Imaging Predicts Sustained Arrhythmic Events in Hypertrophic Cardiomyopathy. Can J Cardiol. 2013;29(3):358-63. doi:10.1016/j.cjca.2012.05.004.

487. Sherrid MV, Massera D. Risk Stratification and Hypertrophic Cardiomyopathy Subtypes. J Am Coll Cardiol. 2019;74(19):2346-9. doi:10.1016/j.jacc.2019.09.020.

488. O’Hanlon R, Grasso A, Roughton M, et al. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2010;56(11):867-74. doi:10.1016/ j.jacc.2010.05.010.

489. Topilsky Y, Pereira NL, Shah DK, et al. Left ventricular assist device therapy in patients with restrictive and hypertrophic cardiomyopathy. Circ Hear Fail. 2011;4(3):266-75. doi:10.1161/CIRCHEARTFAILURE.110.959288.

490. Sreenivasan J, Kaul R, Khan MS, et al. Left Ventricular Assist Device Implantation in Hypertrophic and Restrictive Cardiomyopathy: A Systematic Review. ASAIO J. 2021;67(3):239-44. doi:10.1097/MAT.0000000000001238.

491. Patel SR, Saeed O, Naftel D, et al. Outcomes of Restrictive and Hypertrophic Cardiomyopathies After LVAD: An INTERMACS Analysis. J Card Fail. 2017;23(12):859-67. doi:10.1016/J.CARDFAIL.2017.09.011.

492. Yagi N, Seguchi O, Mochizuki H, et al. Implantation of ventricular assist devices in hypertrophic cardiomyopathy with left ventricular systolic dysfunction. ESC Hear Fail. 2021;8(6):5513-22. doi:10.1002/EHF2.13653.

493. Grupper A, Park SJ, Pereira NL, et al. Role of ventricular assist therapy for patients with heart failure and restrictive physiology: Improving outcomes for a lethal disease. J Heart Lung Transplant. 2015;34(8):1042-9. doi:10.1016/J.HEALUN.2015.03.012.

494. Coutu M, Perrault LP, White M, et al. Cardiac transplantation for hypertrophic cardiomyopathy: a valid therapeutic option. J Heart Lung Transplant. 2004;23(4):413-7. doi:10.1016/S1053-2498(03)00225-0.

495. Диагностикаилечение сердечно-сосудистых заболеваний при беременности 2018. Национальные рекомендации. Российский кардиологический журнал. 2018;(3):91-134. doi:10.15829/1560-4071-2018-3-91-134.

496. Bowyer L. The Confidential Enquiry into Maternal and Child Health (CEMACH). Saving Mothers’ Lives: reviewing maternal deaths to make motherhood safer 2003-2005. The Seventh Report of the Confidential Enquiries into Maternal Deaths in the UK. Obstet Med. 2008;1(1):54. doi:10.1258/om.2008.080017.

497. Billebeau G, Etienne M, Cheikh-Khelifa R, et al. Pregnancy in women with a cardiomyopathy: Outcomes and predictors from a retrospective cohort. Arch Cardiovasc Dis. 2018;111(3):199-209. doi:10.1016/j.acvd.2017.05.010.

498. Krul SP, van der Smagt JJ, van den Berg MP, et al. Systematic Review of Pregnancy in Women With Inherited Cardiomyopathies. Eur J Hear Fail. 2011;13:584-94.

499. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J. 2018;39(34):3165-241. doi:10.1093/eurheartj/ehy340.

500. Regitz-Zagrosek V, Blomstrom Lundqvist C, Borghi C, et al. ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J. 2011;32(24):3147-97. doi:10.1093/EURHEARTJ/ EHR218.

501. Schaufelberger M. Cardiomyopathy and pregnancy. Heart. 2019;105(20):1543-51. doi:10.1136/heartjnl-2018-313476.

502. Goland S, Hagen IM van, Elbaz-Greener G, et al. Pregnancy in women with hypertrophic cardiomyopathy: data from the European Society of Cardiology initiated Registry of Pregnancy and Cardiac disease (ROPAC). Eur Hear J. 2017;38(35):2683-90.

503. Pieper PG, Walker F. Pregnancy in women with hypertrophic cardiomyopathy. Neth Heart J. 2013;21(1):14-8. doi:10.1007/S12471-012-0358-7.

504. Lee MS, Chen W, Zhang Z, et al. Atrial Fibrillation and Atrial Flutter in Pregnant Women-A Population-Based Study. J Am Heart Assoc. 2016;5(4): e003182. doi:10.1161/JAHA.115.003182.

505. Tromp CHN, Nanne ACM, Pernet PJM, et al. Electrical cardioversion during pregnancy: Safe or not? Netherlands Hear J. 2011;19(3):134-6. doi:10.1007/s12471-011-0077-5.

506. Miyoshi T, Kamiya CA, Katsuragi S, et al. Safety and efficacy of implantable cardioverterdefibrillator during pregnancy and after delivery. Circ J. 2013;77(5):1166-70. doi:10.1253/CIRCJ.CJ-12-1275.

507. Elliott P, Spirito P. Prevention of hypertrophic cardiomyopathy-related deaths: Theory and practice. Heart. 2008;94(10):1269-75. doi:10.1136/hrt.2008.154385.

508. Elliott PM, Gimeno JR, Thaman R, et al. Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy. Heart. 2006;92(6):785-91. doi:10.1136/ hrt.2005.068577.

509. Maron BJ, Gardin JM, Flack JM, et al. Prevalence of hypertrophic cardiomyopathy in a general population of young adults: Echocardiographic analysis of 4111 subjects in the CARDIA study. Circulation. 1995;92(4):785-9. doi:10.1161/01.CIR.92.4.785.

510. Robinson K, Frenneaux MP, Stockins B, et al. Atrial fibrillation in hypertrophie cardiomyopathy: A longitudinal study. J Am Coll Cardiol. 1990;15(6):1279-85. doi:10.1016/ S0735-1097(10)80014-2.

511. Monserrat L, Elliott PM, Gimeno JR, et al. Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: An independent marker of sudden death risk in young patients. J Am Coll Cardiol. 2003;42(5):873-9. doi:10.1016/S0735-1097(03)00827-1.

512. Todiere G, Aquaro GD, Piaggi P, et al. Progression of myocardial fibrosis assessed with cardiac magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2012;60(10):922-9. doi:10.1016/j.jacc.2012.03.076.

513. Burton H, Alberg C, Stewart A. Heart to Heart: Inherited Cardiovascular Conditions Services — A Needs Assessment and Service Review. 2009. p. 164. ISBN: 978-1-907198-01-4.

514. Maron BJ, Nishimura RA, Maron MS. Shared decision-making in HCM. Nat Rev Cardiol. 2017;14(3):125-6. doi:10.1038/NRCARDIO.2017.6.

515. Monda E, Limongelli G. The hospitalizations in hypertrophic cardiomyopathy: "The dark side of the moon". Int J Cardiol. 2020;318:101-2. doi:10.1016/J.IJCARD.2020.08.054.

516. Matsubara K, Nakamura T, Kuribayashi T, et al. Sustained cavity obliteration and apical aneurysm formation in apical hypertrophic cardiomyopathy. J Am Coll Cardiol. 2003;42(2):288-95. doi:10.1016/S0735-1097(03)00576-X.

517. Eriksson MJ, Sonnenberg B, Woo A, et al. Long-term outcome in patients with apical hypertrophic cardiomyopathy. J Am Coll Cardiol. 2002;39(4):638-45. doi:10.1016/S07351097(01)01778-8.

518. Chen CC, Lei MH, Hsu YC, et al. Apical hypertrophic cardiomyopathy: correlations between echocardiographic parameters, angiographic left ventricular morphology, and clinical outcomes. Clin Cardiol. 2011;34(4):233-8. doi:10.1002/CLC.20874.

519. Hughes RK, Knott KD, Malcolmson J, et al. Apical Hypertrophic Cardiomyopathy: The Variant Less Known. J Am Heart Assoc. 2020;9(5): e015294. doi:10.1161/JAHA.119.015294.

520. Deva DP, Hanneman K, Li Q, et al. Cardiovascular magnetic resonance demonstration of the spectrum of morphological phenotypes and patterns of myocardial scarring in Anderson-Fabry disease. J Cardiovasc Magn Reson. 2016;18(1):14. doi:10.1186/ S12968-016-0233-6.

521. Ünlü S, Özden Tok Ö, Avcı Demir F, et al. Differential diagnosis of apical hypertrophic cardiomyopathy and apical displacement of the papillary muscles: a multimodality imaging point of view. Echocardiography. 2021;38(1):103-13. doi:10.1111/ECHO.14895.

522. Ruberg FL, Berk JL. Transthyretin (TTR) cardiac amyloidosis. Circulation. 2012;126(10):1286-300. doi:10.1161/CIRCULATIONAHA.111.078915.

523. Efthimiadis GK, Pagourelias ED, Gossios T, Zegkos T. Hypertrophic cardiomyopathy in 2013: Current speculations and future perspectives. World J Cardiol. 2014;6(2):26-37. doi:10.4330/wjc.v6.i2.26.

524. Efthimiadis GK, Pagourelias E, Zegkos T, et al. An Overview of Pharmacotherapy in Hypertrophic Cardiomyopathy: Current Speculations and Clinical Perspectives. Rev Cardiovasc Med. 2016;17(3-4):115-23.